



Market snapshot



Equities - India	Close	Chg .%	CYTD.%
Sensex	38,970	-1.0	8.0
Nifty-50	11,709	-1.0	7.8
Nifty-M 100	17,361	-1.1	-2.9
Equities-Global	Close	Chg .%	CYTD.%
S&P 500	2,864	0.8	14.3
Nasdaq	7,786	1.1	17.3
FTSE 100	7,329	0.2	8.9
DAX	12,143	0.8	15.0
Hang Seng	10,635	0.0	5.0
Nikkei 225	21,272	-0.1	6.3
Commodities	Close	Chg .%	CYTD.%
Brent (US\$/Bbl)	72	-0.7	35.5
Gold (\$/OZ)	1,275	-0.2	-0.6
Cu (US\$/MT)	5,965	-0.6	0.3
Almn (US\$/MT)	1,762	-0.2	-5.4
Currency	Close	Chg .%	CYTD.%
USD/INR	69.7	0.0	-0.1
USD/EUR	1.1	0.0	-2.7
USD/JPY	110.5	0.4	0.7
YIELD (%)	Close	1MChg	CYTDchg
10 Yrs G-Sec	7.3	0.02	-0.1
10 Yrs AAA Corp	8.5	0.02	-0.1
Flows (USD b)	21-May	MTD	CYTD
FIIs	0.17	-0.54	9.06
DIIs	-0.16	1.03	-1.21
Volumes (INRb)	21-May	MTD*	CYTD*
Cash	404	351	356
F&O	5,328	10,815	10,521

Note: *Average

Today's top research idea

Tech Mahindra: Communication and Enterprise swap momentums

- ❖ For FY19, TECHM's USD revenue grew 4.2% YoY, EBITDA increased 34% YoY and PAT was up 13% YoY. Including the buyback of INR19.6b, the total payout for the year stood at 74.5%. For 4QFY19, USD revenue grew 1.9% YoY (our estimate: +3.5% YoY), and was dragged by Enterprise (57.3% of revenues) decline of 2.2% QoQ, v/s our estimate of 1.5% Growth.
- ❖ Adjusted EBITDA margin declined 60bp QoQ to 18.7%, v/s estimate of 19.1%. Going forward, while TECHM continues to expect high-single digit revenue growth with stable margin, the mix of revenue traction is expected to change, with Communications likely taking over from Enterprise. Communications turnaround is a positive for TECHM, but case for upside weakens if Enterprise doesn't compound. Our price target of INR890 discounts forward earnings by 14.5% (5-year average) and implies 15% upside. Maintain Buy.


Research covered

U	
Cos/Sector	Key Highlights
Tech Mahindra	Communication and Enterprise swap momentums
Bosch	Below est.; Negative op. leverage dents margins
United Breweries	Earnings growth hits a bump, long-term outlook intact
Torrent Pharma	Pain points evident across geographies
JSPL	Standalone in line, subs drive miss
CG Consumer Elec.	Marginal miss at operating level as ECD segment disappoints
JK Cements	Increasing utilization setting good stage for rapid capacity expansion
Other notes	INDOSTAR VATW SNGI Telecom
Result Expectation	ASBL BOB CIPLA KKC FCON GETD IIB QUESS SHKL TRCL TMX

пh

Chart of the Day: Tech Mahindra (Communication and Enterprise swap momentums)

Communication revenue seen getting better



Source: MOFSL, Company



In the news today



Kindly click on textbox for the detailed news link

RBI rules out credit line for NBFCs, discusses revised bad loan circular

The Reserve Bank of India (RBI) board on Tuesday suggested not extending a credit line to struggling non-banking financial companies (NBFCs) because it felt there was no systemic liquidity issue but there were solvency concerns in some large entities...

PNB could take control of OBC, Andhra Bank, Allahabad Bank: **Reports**

Punjab National Bank (PNB) could take control of two or three small state-run banks, that could include Oriental Bank of Commerce, Andhra Bank and Allahabad Bank, two sources familiar with the situation told Reuters. New Delhi has been trying to merge smaller regional state-run banks with better managed larger governmentowned lenders as one way to reduce bad loans that stand at more than Rs 9 trillion (\$130 billion), or nearly 5 per cent of the nation's gross domestic output...

3

Competition watchdog probing allegations against Maruti, say reports

4

DHFL puts fresh deposits and renewals on hold, halts premature withdrawals

Dewan Housing Finance Ltd (DHFL), one of India's largest housing finance companies, announced that it has stopped accepting fresh public deposits and renewals of existing deposits with immediate effect. This, in view of the recent revision of the credit rating of its fixed deposit programme...

5

Inside the audit lapses that led to IL&FS crisis

Every time there is corporate scam, audit firms and auditors are the first ones to be blamed. This time, too, after the Infrastructure Leasing and Financial Services Ltd (IL&FS) crisis, the auditors, especially the "big three"-EY, Deloitte and KPMG—are in the dock. Yet, larger questions remain about the changing role of the **Institute of Chartered Accountants** of India (ICAI), besides India's auditing rule. As things stand, IL&FS and its vast network of subsidiaries has now become a PR nightmare for the big three...

6

Opposition ups the ante on tallying EVMs, VVPAT slips


Two days ahead of the announcement the Lok Sabha poll results, 22 Opposition parties have marched to the **Election Commission demanding** a clear procedure in case of any mismatch between the counting figures of electronic voting machines (EVMs) and voterverified paper audit trail (VVPAT) system...

NSE moves SAT against Sebi orders in co-location case

The National Stock Exchange of India (NSE) has challenged the colocation orders of the Securities and Exchange Board of India (Sebi) on the ground that they are unsustainable, arbitrary, and disproportionate. The protracted legal battle is a rare instance of an exchange challenging the market regulator's orders...

22 May 2019







Tech Mahindra

BSE SENSEX	S&P CNX
38,970	11,709
Bloomberg	TECHM IN
Equity Shares (m)	985
M.Cap.(INRb)/(USDb)	761.2 / 10.9
52-Week Range (INR)	846 / 613
1, 6, 12 Rel. Per (%)	-3/1/0
12M Avg Val (INR M)	2529
Free float (%)	64.1

Financials & Valuations (INR b)

Y/E Mar	2019	2021E	2021E
Net Sales	347.4	372.3	410.2
EBITDA	63.4	67.4	75.4
PAT	43.6	48.1	54.3
EPS (INR)	48.2	54.0	61.1
Gr. (%)	12.8	12.1	13.2
BV/Sh (INR)	228.7	240.4	273.1
RoE (%)	22.0	23.1	24.2
RoCE (%)	18.7	19.8	21.0
P/E (x)	16.0	14.3	12.6
P/BV (x)	3.4	3.2	2.8

Estimate change	←
TP change	←
Rating change	←

CMP: INR773 TP: INR890 (+15%)

Buy


Communication and Enterprise swap momentums

- A contrasting year for revenues and margins: For FY19, TECHM's USD revenue grew 4.2% YoY, EBITDA increased 34% YoY and PAT was up 13% YoY. Including the buyback of INR19.6b, the total payout for the year stood at 74.5%. For 4QFY19, USD revenue grew 1.9% YoY (our estimate: +3.5% YoY), EBITDA increased 16% YoY (our estimate: 23%) to INR16.4b, while PAT declined 7% YoY (our estimate: -1% YoY) to INR11.3b.
- **AQFY19 dragged by Enterprise: Communications (42.7% of revenue) surprised positively with sequential growth of 4.4% versus our estimate of ~3%. This was supported partly by seasonality in its products subsidiary Comviva, which was sanguine versus tepid expectations. However, Enterprise (57.3% of revenue) disappointed with a sequential decline of 2.2% in revenue versus our estimate of 1.5% growth. Revenue declined in four of the five verticals in Enterprise. The vertical was marred by the deferral of Healthcare projects into 1Q/2QFY20 and the 3Q base effect for Manufacturing and Retail. Profitability was impacted by a one-time non-recurring expense in SGA, excluding which, the EBITDA margin was 18.7% versus our estimate of 19.1%.
- Expect traction to shift from Enterprise to Communications: TECHM's earlier outlook was of mid-single-digits growth in Communications and 8-10% growth in Enterprise. However, while the overall growth rate may remain in high-single-digits, Communications will likely be better, while Enterprise may soften. Three quarters of healthy growth, coupled with a strong order book, drive confidence in Communications. For margins, TECHM expects to maintain current levels at the least, despite 1QFY20 facing headwinds from wage hikes, visa costs and Comviva seasonality. Subsidiary companies' margins and utilization remain levers over the near term, while offshore revenue percentage is a medium- to long-term lever.
- Valuation view: We cut our revenue estimates for FY20/21 by ~1pp, mainly on the back of the 4Q miss and the softer outlook on Enterprise. We were already building in a gradual improvement in Communications on the back of service providers' 5G investments. We continue estimating an EBITDA margin band of 18-18.5%. Our earnings estimates are little changed post the results. Over FY19-21, we expect USD revenue CAGR of 8% and earnings CAGR of 13%. Our TP of INR890 (15% upside) discounts forward earnings by 14.5x, the average multiple over the last five years. Maintain Buy.



Quarterly Performance (Consolidated)

Y/E March		FY	'18			FY	19		FY18	FY19	Est.	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4Q	(% / bp)
Revenue (USD m)	1,138	1,179	1,209	1,244	1,224	1,218	1,261	1,268	4,771	4,971	1,288	-1.6
QoQ (%)	0.6	3.6	2.5	2.9	-1.6	-0.5	3.5	0.5	9.6	4.2	2.2%	51bp
Revenue (INR m)	73,361	76,064	77,760	80,545	82,763	86,298	89,437	88,923	3,07,730	3,47,421	90,810	-2.1
YoY (%)	6.0	6.1	2.9	7.5	12.8	13.5	15.0	10.4	5.6	12.9	12.7	-234bp
GPM (%)	28.0	29.3	30.8	31.9	30.7	34.0	33.1	33.1	30.0	32.8	33.0	9bp
SGA (%)	15.3	14.7	14.6	14.3	14.3	15.3	13.8	14.7	14.7	14.5	13.9	78bp
EBITDA	9,347	11,057	12,638	14,119	13,569	16,186	17,226	16,387	47,161	63,368	17,360	-5.6
EBITDA Margin (%)	12.7	14.5	16.3	17.5	16.4	18.8	19.3	18.4	15.3	18.2	19.1	-69bp
EBIT Margin (%)	9.4	11.0	12.7	13.8	13.0	15.3	16.1	15.4	11.8	15.0	15.9	-56bp
Other income	4,106	3,222	2,250	4,513	1,114	1,751	806	1,671	14,091	5,342	2,139	-21.9
Interest expense	370	386	341	527	305	388	358	281	1,624	1,332	344	-18.3
ETR (%)	25.4	25.3	21.8	18.6	21.2	26.8	17.8	23.5	22.4	22.4	25.0	
PAT excl. BT amort & EOI	7,985	8,362	9,422	12,221	8,979	10,642	12,029	11,325	37,990	42,975	12,092	-6.3
QoQ (%)	35.8	4.7	12.7	29.7	-26.5	18.5	13.0	-5.9			0.5	
YoY (%)	21.7	29.7	10.1	107.9	12.4	27.3	27.7	-7.3	38.3	13.1	-1.1	
EPS (INR)	9.0	9.4	10.6	13.7	10.1	11.9	13.5	12.6	42.6	47.7	13.5	
Headcount	1,15,990	1,17,225	1,15,241	1,12,807	1,13,552	1,18,391	1,21,842	1,21,082	1,12,807	1,21,082	1,25,491	-3.5
Util excl. trainees (%)	77.0	81.0	83.0	84.0	81.0	81.0	82.0	82.0	81.1	81.5	81.9	10bp
Attrition (%)	17.0	16.0	17.0	18.0	19.0	20.0	21.0	21.0				
Offshore rev. (%)	36.3	35.9	34.2	33.0	33.4	35.5	34.5	34.8	34.8	34.5	34.7	10bp





Bosch

BSE SENSEX	S&P CNX
38,970	11,709
Bloomberg	BOS IN
Equity Shares (m)	31
M.Cap.(INRb)/(USDb)	513 / 7.4
52-Week Range (INR)	22400 / 16686
1, 6, 12 Rel. Per (%)	-4/-20/-14
12M Avg Val (INR M)	379
Free float (%)	29.5
·	•

Financials & Valuations (INR b)

Y/E Mar	2019	2020E	2021E
Net Sales	122.6	137.1	161.0
EBITDA	21.6	25.3	30.5
PAT	16.0	17.1	19.9
EPS (INR)	541.9	578.4	673.9
Gr. (%)	15.3	6.7	16.5
BV/Sh (INR)	3,095	2,707	3,106
RoE (%)	16.7	19.9	23.2
RoCE (%)	24.6	29.7	34.5
P/E (x)	32.1	30.1	25.8
P/BV (x)	5.6	6.4	5.6

Estimate change	
TP change	
Rating change	—

TP: INR18,200 (+5%) CMP: INR17,394 Neutral

Below est.; Negative op. leverage dents margins; FY20 outlook cautious

- Revenues declined 13% YoY (-11% QoQ) to INR27.5b (our est. INR30.5b). Auto revenue declined 16% YoY (domestic auto revenues fell 16.4% while auto exports declined 6.3%). Powertrain revenues declined 19% impacted by diesel, even as gasoline grew in line with the industry. EBITDA declined 25% YoY (-22% QoQ) to INR5.2b (below our est. INR6b). EBITDA margin shrank 310bp YoY to 18.8% (our est. 19.8%) impacted by negative operating leverage. Lower tax restricted the decline in PAT to 17% YoY at INR4.1b (our est. INR4.4b). In FY19, Revenue/EBITDA/PAT grew 5%/3.4%/11.5%.
- Concall highlights: (a) FY20 outlook cautious due to BS6 transition, but growth expected from 2HFY20. It expects OEMs to stop manufacturing BS4 vehicles latest by end-3QFY20. (b) Aftermarket business grew 8-10% in CY18, but, 1QCY19 growth was muted. (c) BOS has ~33% market share in the gasoline business; it is growing in line with industry. (d) Capex: ~INR6b in FY19 and INR5-6b in FY20. (e) For BS6, customer acquisitions (incl. 2Ws) are at an all-time high for BOS (currently working on 150 projects).
- Valuation view: We have reduced our FY20/FY21 EPS estimates by 6%/7% to factor in the weak demand environment. BS6 transition poses the risk of (a) further market share loss in CVs, and (b) continuous decline in its stronghold — diesel PVs, though 2W opportunity should open up for BOS (it's one of the 3-4 players in 2W EFIs). BOS' earnings have been flat over the last three years. While we estimate EPS to grow at ~11.5% CAGR over FY19-21, the changing competitive positioning poses a threat to our estimates. Valuations have corrected, in line with muted earnings growth and dilution in competitive positioning. The stock now trades at 30.1x/25.8x FY20/FY21 EPS (v/s 10-year LPA at ~32x). Maintain **Neutral** with TP of ~INR18,200 (27x FY21EPS - ~15% discount to LPA).

Quarterly performance (S/A) (INR Million)												
Y/E March		FY	18			FY1	L9		FY18	FY19	Est	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Net Sales	26,484	28,119	30,719	31,580	32,122	32,011	30,955	27,492	116,902	122,579	30,458	-9.7
YoY Change (%)	4.2	6.8	14.1	22.7	21.3	13.8	0.8	-12.9	12.0	4.9	-3.6	
RM Cost (% of sales)	54.4	55.1	52.8	53.5	54.4	56.7	55.5	54.3	53.9	55.3	54.7	-40bp
Staff Cost (% of sales)	12.9	12.2	11.1	10.4	10.9	10.6	10.9	12.4	11.6	11.2	11.2	120bp
Other Exp. (% of sales)	16.2	14.5	21.5	14.2	15.1	14.0	19.9	14.5	16.6	15.9	14.2	20bp
EBITDA	4,390	5,080	4,476	6,914	6,282	5,962	4,226	5,165	20,933	21,635	6,037	-14.4
Margins (%)	16.6	18.1	14.6	21.9	19.6	18.6	13.7	18.8	17.9	17.7	19.8	-100bp
Depreciation	1,062	1,108	1,243	1,259	939	950	1,012	1,144	4,672	4,045	1,087	
Interest	5	0	27	1	0	0	102	31	33	133	0	
Other Income	1,295	1,290	1,023	1,582	1,147	1,395	1,786	1,625	5,118	5,953	1,638	
PBT before EO expense	4,618	5,262	4,229	7,236	6,489	6,407	4,899	5,615	21,346	23,410	6,588	-14.8
Extra-Ord expense	0	0	0	939	0	0	0	0	939	0	0	
PBT after EO Expense	4,618	5,262	4,229	6,297	6,489	6,407	4,899	5,615	20,407	23,410	6,588	-14.8
Tax Rate (%)	34.5	32.8	33.6	31.1	33.6	34.4	31.5	26.7	32.8	31.7	33.2	-650bp
Reported PAT	3,026	3,533	2,810	4,338	4,310	4,200	3,354	4,117	13,708	15,980	4,400	-6.4
Adj PAT	3,026	3,533	2,810	4,985	4,310	4,200	3,354	4,117	14,339	15,980	4,400	-6.4
YoY Change (%)	-19.3	-16.5	30.8	13.2	42.4	18.9	19.3	-17.4	4.7	11.5	-11.7	

22 May 2019 5



United Breweries

09 IN
IN
64
.4
30
12
54

Financials & Valuations (INR b)

Y/E Mar	FY19	FY20E	FY21E
Net Sales	64.8	72.5	83.4
EBITDA	11.4	12.6	15.2
PAT	5.6	6.3	7.7
EPS (INR)	21.3	23.9	29.3
Gr. (%)	42.8	12.1	22.6
BV/Sh (INR)	119.8	140.5	166.0
RoE (%)	19.2	18.3	19.1
RoCE (%)	18.5	17.7	18.3
P/E (x)	67.1	59.8	48.8
EV/EBITDA (x)	33.2	30.0	25.0

Estimate change	↓
TP change	I I
Rating change	←

CMP: INR1,428 TP: INR1,430 Neutral

Earnings growth hits a bump, long-term outlook intact

- 4QFY19 standalone net sales grew 10.7% YoY (off a strong base) to INR16.3b (our est. INR16.5b). EBITDA declined 17.8% YoY to INR1.7b (our est. INR2.5b), while Adj. PAT declined 25.3% YoY to INR679m (our est. INR1.1b). Volumes are estimated to have grown at 9% with likely market share gains as well.
- Standalone Gross margins declined 220bp YoY (our est. -60bp) to 50.5% likely due to higher barley costs. Employee costs were up 10bp YoY to 7.6% while other expenses were up 130bp to 32.4%. Consequently, standalone EBITDA margins were down 360bp YoY to 10.5% (our est. 15.0%).
- **FY19 consolidated performance:** Net Sales/EBITDA/PAT saw YoY increase of 15.2%/26.2%/42.8%. Gross margins improved 40bp YoY to 53.6% and EBITDA Margin by 150bp YoY to 17.6%. Strong FY19 PAT growth was on top of the 71.6% PAT growth seen in full-year FY18.
- Balance sheet details: Working Capital was well managed with Net Working Capital increasing 9.4% v/s 15.2% increase in sales for the full year. Net debt declined sharply by 85% YoY. Negative factor in the balance sheet was the ~40% sharp increase in total other assets (incl. short term and long term).
- Valuation and view: Significant expectations miss in 4QFY19 resulted in 10.9%/8.5% decrease in FY20/FY21 EPS. We had downgraded the stock to Neutral in Mar'19 citing likely sharp reduction in near-term earnings growth; this, after two stellar years of EPS growth (72% in FY18 and 43% in FY19). But, the EPS cuts have exceeded our earlier expectations. Near-term election related disruptions, rising barley costs and ongoing high capex intensity should limit EPS growth to ∼12% in FY20. Nevertheless, long-term volume and earnings growth opportunity (FY19 PAT at only USD80m) is immense for India's largest beer player, especially in a sector with strong entry barriers in the form of distribution, brewery reach, scale and brands.
- Valuing the company at 25x FY21 EV/EBITDA (in line with peers), we get a target price of INR1,430. Maintain Neutral.

				•							
											INR m
FY18			FY19				Consol.	Consol.	FY19	Variance	
Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY18	FY19	4QE	Variance
0 1	12,796	11,994	14,718	18,659	15,260	14,512	16,294	56,190	64,754	16,476	-1.1%
.3	23.4	17.3	32.3	11.2	19.3	21.0	10.7	18.7	15.2	12.1	
.7	6,907	6,272	7,762	10,095	8,485	7,739	8,230	29,876	34,678	8,588	
.5	54.0	52.3	52.7	54.1	55.6	53.3	50.5	53.2	53.6	52.1	
34	2,219	1,526	2,082	4,004	3,182	2,479	1,712	9,020	11,384	2,471	-30.7%
.4	83.1	19.3	105.9	25.8	43.4	62.4	-17.8	41	26.2	19	
.0	17.3	12.7	14.1	21.5	20.9	17.1	10.5	16.1	17.6	15.0	
19	650	650	648	637	656	665	639	2,597	2,599	761	
2	127	93	114	92	40	62	118	477	312	69	
3	12	8	48	153	37	21	106	131	320	40	
6	1,454	791	1,368	3,428	2,523	1,772	1,062	6,078	8,793	1,681	-36.8%
37	515	317	459	1,208	885	681	383	2,132	3,160	555	
.1	35.4	40.1	33.6	35.3	35.1	38.4	36.0	35	35.9	33	
0	0	0	0	0	0	0	0	-4	-4	4.0	
.9	938	474	909	2,219	1,638	1,092	679	3,942	5,629	1,122	-39.5%
.1	246.9	-2.3	1,250.4	37.1	74.5	130.4	-25.3	71.7	42.8	23.5	
.6	7.3	4.0	6.2	11.9	10.7	7.5	4.2	7.0	8.7	6.8	
	.Q	FY1 Q 2Q 30 12,796 .3 23.4 17 6,907 .5 54.0 34 2,219 .4 83.1 .0 17.3 49 650 42 127 53 12 56 1,454 87 515 .1 35.4 0 0 19 938 .1 246.9	FY18 Q 2Q 3Q 30 12,796 11,994 .3 23.4 17.3 17 6,907 6,272 .5 54.0 52.3 84 2,219 1,526 .4 83.1 19.3 .0 17.3 12.7 49 650 650 42 127 93 63 12 8 66 1,454 791 6.1 35.4 40.1 0 0 0 19 938 474 .1 246.9 -2.3	FY18 Q 2Q 3Q 4Q 30 12,796 11,994 14,718 .3 23.4 17.3 32.3 17 6,907 6,272 7,762 .5 54.0 52.3 52.7 84 2,219 1,526 2,082 .4 83.1 19.3 105.9 .0 17.3 12.7 14.1 19 650 650 648 12 127 93 114 153 12 8 48 165 1,454 791 1,368 17 515 317 459 .1 35.4 40.1 33.6 0 0 0 0 0 19 938 474 909 .1 246.9 -2.3 1,250.4	FY18 Q 2Q 3Q 4Q 1Q 11,796 11,994 14,718 18,659 .3 23.4 17.3 32.3 11.2 17 6,907 6,272 7,762 10,095 .5 54.0 52.3 52.7 54.1 84 2,219 1,526 2,082 4,004 .4 83.1 19.3 105.9 25.8 .0 17.3 12.7 14.1 21.5 19 650 650 648 637 12 127 93 114 92 13 12 8 48 153 12 8 48 153 13 12 8 48 153 13 13 14 92 14 1 35.4 40.1 33.6 35.3 15 938 474 909 2,219 11 246.9 -2.3 1,250.4 37.1	FY18 FY2 Q 2Q 3Q 4Q 1Q 2Q 30 12,796 11,994 14,718 18,659 15,260 .3 23.4 17.3 32.3 11.2 19.3 17 6,907 6,272 7,762 10,095 8,485 .5 54.0 52.3 52.7 54.1 55.6 34 2,219 1,526 2,082 4,004 3,182 .4 83.1 19.3 105.9 25.8 43.4 .0 17.3 12.7 14.1 21.5 20.9 49 650 650 648 637 656 42 127 93 114 92 40 53 12 8 48 153 37 56 1,454 791 1,368 3,428 2,523 37 515 317 459 1,208 885 3.1	FY18 FY19 Q 2Q 3Q 4Q 1Q 2Q 3Q 12,796 11,994 14,718 18,659 15,260 14,512 3 23.4 17.3 32.3 11.2 19.3 21.0 17 6,907 6,272 7,762 10,095 8,485 7,739 .5 54.0 52.3 52.7 54.1 55.6 53.3 4 2,219 1,526 2,082 4,004 3,182 2,479 .4 83.1 19.3 105.9 25.8 43.4 62.4 .0 17.3 12.7 14.1 21.5 20.9 17.1 49 650 650 648 637 656 665 42 127 93 114 92 40 62 53 12 8 48 153 37 21 56 1,454 791 1,368 3,428 2,523 1,772 57 515 317 459 1,208 885 681 .1 35.4 40.1 33.6 35.3 35.1 38.4 0 0 0 0 0 0 0 0 0 19 938 474 909 2,219 1,638 1,092 .1 246.9 -2.3 1,250.4 37.1 74.5 130.4	FY18 FY19 Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 30 12,796 11,994 14,718 18,659 15,260 14,512 16,294 .3 23.4 17.3 32.3 11.2 19.3 21.0 10.7 17 6,907 6,272 7,762 10,095 8,485 7,739 8,230 .5 54.0 52.3 52.7 54.1 55.6 53.3 50.5 34 2,219 1,526 2,082 4,004 3,182 2,479 1,712 .4 83.1 19.3 105.9 25.8 43.4 62.4 -17.8 .0 17.3 12.7 14.1 21.5 20.9 17.1 10.5 49 650 650 648 637 656 665 639 42 127 93 114 92 40 62 118 53	FY18 FY19 Consol. Q 2Q 3Q 4Q 1Q 1Q 2Q 3Q 4Q FY18 30 12,796 11,994 14,718 18,659 15,260 14,512 16,294 56,190 .3 23.4 17.3 32.3 11.2 19.3 21.0 10.7 18.7 17 6,907 6,272 7,762 10,095 8,485 7,739 8,230 29,876 .5 54.0 52.3 52.7 54.1 55.6 53.3 50.5 53.2 34 2,219 1,526 2,082 4,004 3,182 2,479 1,712 9,020 .4 83.1 19.3 105.9 25.8 43.4 62.4 -17.8 41 .0 17.3 12.7 14.1 21.5 20.9 17.1 10.5 16.1 49 650 650 648 637 656 665 639 2,597 42 127 93 114 92 40 62 118 477 53 12 8 48 153 37 21 106 131 56 1,454 791 1,368 3,428 2,523 1,772 1,062 6,078 37 515 317 459 1,208 885 681 383 2,132 .1 35.4 40.1 33.6 35.3 35.1 38.4 36.0 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -4 19 938 474 909 2,219 1,638 1,092 679 3,942 .1 246.9 -2.3 1,250.4 37.1 74.5 130.4 -25.3 71.7	FY18 FY19 Consol. Consol. Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q FY18 FY19 30 12,796 11,994 14,718 18,659 15,260 14,512 16,294 56,190 64,754 .3 23.4 17.3 32.3 11.2 19.3 21.0 10.7 18.7 15.2 17 6,907 6,272 7,762 10,095 8,485 7,739 8,230 29,876 34,678 .5 54.0 52.3 52.7 54.1 55.6 53.3 50.5 53.2 53.6 34 2,219 1,526 2,082 4,004 3,182 2,479 1,712 9,020 11,384 .4 83.1 19.3 105.9 25.8 43.4 62.4 -17.8 41 26.2 .0 17.3 12.7 14.1 21.5 20.9 17.1 10.5 16.1 17.6	FY18 FY19 Consol. Consol. FY19 4QE Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q FY19 4QE 30 12,796 11,994 14,718 18,659 15,260 14,512 16,294 56,190 64,754 16,476 3 23.4 17.3 32.3 11.2 19.3 21.0 10.7 18.7 15.2 12.1 47 6,907 6,272 7,762 10,095 8,485 7,739 8,230 29,876 34,678 8,588 .5 54.0 52.3 52.7 54.1 55.6 53.3 50.5 53.2 53.6 52.1 34 2,219 1,526 2,082 4,004 3,182 2,479 1,712 9,020 11,384 2,471 .4 83.1 19.3 105.9 25.8 43.4 62.4 -17.8 41 26.2 19 .0



Torrent Pharmaceuticals

BSE SENSEX	S&P CNX
38,970	11,709
Bloomberg	TRP IN
Equity Shares (m)	169
M.Cap.(INRb)/(USDb)	270.9 / 3.9
52-Week Range (INR)	1964 / 1282
1, 6, 12 Rel. Per (%)	-12/-14/7
12M Avg Val (INR M)	472
Free float (%)	28.8

Y/E Mar	2019	2020E	2021E
Net Sales	76.1	84.1	94.6
EBITDA	19.5	21.7	25.0
PAT	7.2	9.0	12.3
EPS (INR)	42.7	53.0	72.6
Gr. (%)	-7.1	24.1	36.8
BV/Sh (INR)	279.2	314.2	360.6
RoE (%)	15.5	17.9	21.5
RoCE (%)	11.9	12.8	15.6
P/E (x)	37.3	30.1	22.0
P/BV (x)	5.7	5.1	4.4


Estimate change	
TP change	
Rating change	←

CMP: INR1,601 TP: INR1,500 (-6%) Neutral

Pain points evident across geographies; success in course correction key

- Sales growth subdued: Sales increased 8% YoY to INR18.5b (our estimate: INR21.1b) in 4QFY19, supported by the US (+21% YoY to INR3.7b; +11% YoY to USD52m in USD terms) and India (DF; +9% YoY to INR7.5b) businesses. However, Germany (+2% YoY to INR2.3b) and Brazil (-4% YoY to INR2b) businesses exhibited a muted performance.
- Profitability supported by a favorable base: Gross margin (GM) shrank 170bp YoY (+50bp QoQ) to 70.7% due to a change in the product mix. However, EBITDA margin expanded 440bp YoY to 25.5% (our estimate: 26.9%), led by lower other expenses (-680bp YoY off a high base). EBITDA of INR4.7b (up 14% YoY) came in below our estimate of INR5.7b. In 4QFY19, TRP incurred an extraordinary expense of INR3.6b toward (a) an impairment related to Bio-Pharm (INR2.2b) and (b) a penalty on product recall in the US (INR1.4b). Adjusted for this, PAT stood at INR1.6b (our estimate: PAT of INR2.7b) up 12.5% YoY.
- For FY19, sales/EBITDA stood at INR76b (+27% YoY)/INR19.5b (+44% YoY), while PAT came in at INR7.2b (down 7% YoY)
- Key concall highlights: (a) The discontinuation of Losartan/Losartan H and the shutdown of the Pennsylvania site impacted US growth. (b) India sales growth was affected by discontinuation of a few products/productivity initiatives. Adjusted for the same, India sales growth was higher at 11% YoY.
- Valuation and view: There would be medium term weakness in financial performance due (a) supply disruption in a few products for the US market, (b) moderate growth in DF, (c) increased opex for its Pennsylvania site and (d) reduced operating leverage. Accordingly, we lower our EPS estimate for FY20/21 by 23%/13% to INR53/INR73. We roll to 20x (unchanged) 12M forward earnings and arrive at a TP of INR1,500 (prior: INR1,660). We await clarity on classification of the recent USFDA inspection at its key formulation sites (Dahej/Indrad). Maintain Neutral.

Quarterly performance (Consolidated	-1											Million)
Y/E March		FY1	8			FY1	9		FY18	FY19	Est.	Var.
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	vs Est
Net Revenues	13,740	14,290	14,770	17,220	18,720	18,940	19,880	18,560	60,020	76,100	21,185	-12.4%
YoY Change (%)	-8.8	1.6	4.5	24.7	36.2	32.5	34.6	7.8	2.5	26.8	23.0	
EBITDA	2,970	3,290	3,590	4,140	4,770	4,730	5,260	4,730	13,990	19,490	5,709	-17.1%
Margins (%)	21.6	23.0	24.3	24.0	25.5	25.0	26.5	25.5	23.3	25.6	26.9	
Depreciation	800	840	940	1,510	1,500	1,520	1,560	1,600	4,090	6,180	1,533	
Interest	560	510	800	1,210	1,220	1,260	1,330	1,230	3,080	5,040	1,192	
Other Income	1,050	780	740	420	270	100	30	170	2,990	570	300	
PBT before EO Expense	2,660	2,720	2,590	1,840	2,320	2,050	2,400	2,070	9,810	8,840	3,284	
Extra-Ord Expense	0	0		500	0	0	-350	3,570	500	3,220	0	
PBT after EO Expense	2,660	2,720	2,590	1,340	2,320	2,050	2,750	-1,500	9,310	5,620	3,284	
Tax	780	680	2,010	-940	690	260	290	20	2,530	1,260	570	
Rate (%)	29.3	25.0	77.6	-51.1	29.7	12.7	12.1	1.0	25.8	14.3	17.3	
Reported PAT	1,880	2,040	580	2,280	1,630	1,790	2,460	-1,520	6,780	4,360	2,714	
Adj PAT	1,880	2,040	2,390	1,472	1,630	1,790	2,152	1,656	7,782	7,228	2,714	-39.0%
YoY Change (%)	-35.6	-30.1	15.5	-35.7	-13.3	-12.3	-9.9	12.5	-16.6	-7.1	-2.4	
Margins (%)	13.7	14.3	16.2	8.5	8.7	9.5	10.8	8.9	13.0	9.5	12.8	



Buy





Jindal Steel and Power

 BSE SENSEX
 S&P CNX

 38,970
 11,709

CMP: INR163 TP: INR268 (+64%)

Conference Call Details



Date: 22nd May 2019 Time: 12:00 IST Dial-in details: ++91 (22) 6280 1384

Financials & Valuations (INR b)

Financials & Valuations (INK D)										
Y/E March	2019	2020E	2021E							
Sales	393.7	393.0	418.2							
EBITDA	84.1	88.6	98.9							
Adj. PAT	-1.7	-1.1	22.9							
Adj. EPS (INR)	-1.7	-1.1	23.5							
EPS Gr(%)	-79.5	-37.7	-2,262.3							
BV/Sh. (INR)	296.9	294.6	317.7							
RoE (%)	-0.6	-0.4	7.7							
RoCE (%)	3.7	6.0	8.4							
Payout (%)	0.0	0.0	0.0							
Valuations										
P/E (x)	-93.6	-150.2	6.9							
P/BV	0.5	0.6	0.5							
EV/EBITDA (x)	7.1	6.5	5.7							
Div. Yield (%)	0.0	0.0	0.0							

Standalone in line, subs drive miss

4QFY19 consol. EBITDA of INR18.4b (our estimate: INR21b) was down 11% QoQ. EBITDA was in line with our estimate at the standalone level, but lower than estimate at subsidiaries. Interest cost increased 12% QoQ to INR11.6b. Depreciation charge of INR23b includes an impairment charge of INR12.8b for Australia coal mines, excluding which depreciation was flat QoQ. Exceptional charge of INR17.3b includes (a) INR12.7b for coal penalty paid in 2015 written-off and (b) INR3.7b duty and asset write-off. Cash PAT (pre-exceptional) was down 35% QoQ to INR6.8b. Net debt (ex-acceptances) declined INR1.1b QoQ to INR390.8b.

- Standalone (S/A): Steel sales were at 1.45mt (+21% QoQ, 23% YoY). Implied steel realization was at INR47,500/t (-10% QoQ). EBITDA/t was down by INR2,400 QoQ at INR9,931 due to lower steel spreads, partly offset by lower cost. EBITDA was at INR14.4b (-3% QoQ, in-line).
- JPL: Generation was at 2.6BU (13% YoY). Realization came in at INR4.16/kWh (-2% QoQ, -7% YoY). EBITDA/kWh was at INR1.1 (-4% QoQ, -11% YoY). EBITDA was at INR2.7b (-2% QoQ, +1% YoY) v/s our estimate of INR4b.
- Oman: Steel sales were at 460kt (+2% QoQ). EBITDA/t of USD81 was up USD10 QoQ. EBITDA came in at INR2.5b (our estimate: INR3.6b).
- Other subs: EBITDA was at -INR1.1b v/s +INR1b in 3Q.

We value the stock at INR268/sh on FY20E SOTP. Maintain Buy.

Quarterly Performance (Consolidated) - INR m

Y/E March	FY18 FY19			FY18				FY19				vs Est
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Net Sales	59,096	61,234	69,926	85,988	96,654	99,823	95,656	101,590	276,244	393,721	97,767	4
Change (YoY %)	26.9	31.2	29.3	36.7	63.6	63.0	36.8	18.1	31.4	42.5	13.7	
EBITDA	13,527	13,734	16,065	21,365	22,766	22,074	20,769	18,447	64,691	84,056	21,030	-12
Change (YoY %)	37.5	61.9	25.8	37.7	68.3	60.7	29.3	-13.7	38.8	29.9	-1.6	
As % of Net Sales	22.9	22.4	23.0	24.8	23.6	22.1	21.7	18.2	23.4	21.3	21.5	
Interest	9,006	9,268	9,670	10,714	9,729	10,858	10,424	11,631	38,657	42,642	10,478	11
Depreciation	9,622	9,977	9,632	9,599	10,399	10,314	10,357	23,733	38,830	54,804	10,738	121
Other Income	0	14	10	5	0	9	148	0	29	157	9	
PBT (before EO item)	-5,101	-5,496	-3,227	1,057	2,637	911	136	-16,917	-12,767	-13,233	-178	9,402
Extra-ordinary Income	0	-1,497	0	-4,376	0	2,555	0	-17,339	-5,874	-14,784	0	
PBT (after EO item)	-5,101	-6,994	-3,227	-3,319	2,637	3,466	136	-34,255	-18,641	-28,017	-178	19,141
Total Tax	-887	-1,999	-457	944	1,538	674	1,008	-7,122	-2,398	-3,902	702	
% Tax	17.4	28.6	14.2	-28.4	58.3	19.4	741.5	20.8	12.9	13.9	-394.3	
Reported PAT	-4,214	-4,995	-2,770	-4,264	1,099	2,792	-872	-27,133	-16,243	-24,115	-880	2,983
MI - Loss/(Profit)	-334	-497	-67	-1,166	-709	-645	-614	-5,676	-2,064	-7,644	-654	
Associate	10	19	43	17	0	0	0	0	87	0	26	
Adjusted PAT	-3,871	-2,982	-2,660	1,295	1,808	882	-258	-4,119	-8,218	-1,687	-200	1,958
Change (YoY %)	-15.2	-60.0	-34.7	-142.8	-146.7	-129.6	-90.3	-418.0	-57.0	-79.5	-115.4	





21 May 2019 Results Flash | Sector: Capital Goods

CG Consumer Electrical

BSE SENSEX S&P CNX 38,970 11,709

CMP: INR222 TP: INR270 (+20%)

Buy

Conference Call Details



Date: 22nd May 2019 Time: 11:00am IST Dial-in details: +91-22-62801259

Financials & Valuations (INR b)

Y/E March	2019	2020E	2021E
Net Sales	45.0	51.7	59.4
EBITDA	6.0	7.3	8.6
NP	3.8	4.8	5.8
EPS (INR)	6.0	7.7	9.3
EPS Gr. (%)	16.1	27.6	21.6
BV/Sh. (INR)	15.7	19.6	24.3
RoE (%)	42.4	43.4	42.4
RoCE (%)	27.1	31.9	37.8
P/E (x)	38.0	30.1	25.3
Div. Yield	1.1	1.4	1.7

Marginal miss at operating level as ECD segment disappoints

Lighting margins back to double-digits

- Sales stood at INR12.1b (+7% YoY), marginally below our estimate of INR12.3b. The revenue miss was on account of lower-than-estimated ECD sales. Revenue grew 9.6% YoY to INR8.6b. Lighting revenue grew a tepid 1.4% YoY to INR3.4b.
- EBITDA grew 3% YoY to INR1.7b and was 6% below expectation. EBITDA margin came in at 14% (-60bp YoY) v/s expectation of 14.5%.
- EBIT margins for the Lighting division stood at 11.5%, while EBIT margins for the ECD segment came in at 19.5% (4QFY18 21.7%).
- Other income was higher than expectation at INR172m.
- Tax write-back of INR284.5m boosted reported PAT, which stood at INR1.4b (+37% YoY).
- Adj. PAT stood at INR1.13b (+10% YoY) and was 1.5% below our expectation.

Quarterly Estimates (Standalone)										(INR M)		
		FY1	L 8			FY	19		FY18	FY19	Vs Est.	Var.
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4Q	(%)
Sales	10,554	9,597	9,382	11,263	12,039	10,378	10,303	12,069	40,797	44,789	12,318	-2.0%
Change (%)	-3.7	9.8	6.7	7.6	14.1	8.1	9.8	7.2	4.6	9.8	9.4	
EBITDA	1,294	1,207	1,165	1,645	1,673	1,239	1,261	1,685	5,310	5,858	1,785	-5.6%
Change (%)	-17.8	19.3	19.8	27.5	29.3	2.7	8.3	2.5	9.6	10.3	8.5	
As of % Sales	12.3	12.6	12.4	14.6	13.9	11.9	12.2	14.0	13.0	13.1	14.5	
Depreciation	32	32	32	31	31	32	33	33	126	129	38	
Interest	162	157	158	161	152	150	150	143	637	596	159	
Other Income	97	35	66	109	88	98	124	172	308	483	128	
PBT	1,198	1,054	1,040	1,562	1,578	1,155	1,202	1,681	4,854	5,616	1,717	-2.1%
Tax	395	346	345	530	535	386	405	549	1,617	1,875	567	
Effective Tax Rate (%)	33.0	32.8	33.2	33.9	33.9	33.4	33.7	32.7	33.3	33.4	33.0	
Adjusted PAT	802	708	695	1,032	1,043	769	797	1,132	3,238	3,741	1,149	-1.5%
Change (%)	(14.2)	22.3	27.9	29.0	30.0	8.6	14.7	9.7	14.3	15.5	11.3	
Extra-ordinary Income (net)	-	-	-	-	-	-	-	284.5		284.5	-	
Reported PAT	802	708	695	1,032	1,043	769	797	1,417	3,238	4,025	1,149	23.3%
Change (%)	(14.2)	23.3	27.9	32.4	30.0	8.6	14.7	37.3	14.3	24.3	11.3	



J K Cement

(INID MIIIIon)

BSE SENSEX	S&P CNX
38,970	11,709
Bloomberg	JKCE IN
Equity Shares (m)	77.3
M.Cap.(INRb)/(USDb)	53.3 / 0.8
52-Week Range (INR)	1194 / 650
1, 6, 12 Rel. Per (%)	-8/-31/-36
12M Avg Val (INR M)	44
Free float (%)	35.8

Financial	ls & Val	luations	INR b
-----------	----------	----------	-------

Y/E Mar	2019	2020E	2021E
Net Sales	52.6	60.1	67.7
EBITDA	8.3	9.9	11.9
PAT	2.6	3.2	4.1
EPS (INR)	34.1	41.9	52.7
Gr. (%)	-16.8	22.9	25.7
BV/Sh (INR)	348.8	382.3	426.5
RoE (%)	11.3	11.5	13.0
RoCE (%)	8.5	8.9	9.9
P/E (x)	27.7	22.5	17.9
P/BV (x)	2.7	2.5	2.2
EV/EBITDA (x)	10.1	10.0	7.8
EV/Ton (USD)	97	83	78
·			

Estimate change	\longrightarrow
TP change	←
Rating change	\longrightarrow

CMP: INR944 TP: INR1,155 (+22%) Buy

Increasing utilization setting good stage for rapid capacity expansion

- Grey cement utilization now at 96%; white cement volume growth healthy: Grey cement volumes (incl. clinker) increased by 5.5% YoY to 2.53mt (~96% utilization), while white cement volumes were up 9% YoY to 0.35mt in 4QFY19. Combined realizations stood at INR5,182/ton (+7% YoY). Revenue increased 13% YoY to INR14.9b (in-line) in the quarter.
- Healthy realizations boost profitability: Blended EBITDA/t increased 45% YoY to INR971 due to healthy realization, partially offset by a marginal rise in cost/t. EBITDA grew 54% YoY to INR2.8b (in-line), with the margin expanding 4.9pp YoY to 18.7%. Tax rate was at 29% in the quarter, as against 22% in the yearago period. Consequently, PAT grew 43% YoY to INR 1.5b (in-line).
- **FY19 performance:** Volumes grew 5% YoY, while net sales were up 8.5% to INR50b. EBITDA increased 7% to INR8.1b. PAT was up 6% to INR3.25b.
- Concall highlights: (1) Expansion plans are at advanced stages of execution expect commissioning of (a) the clinker line and the 2mt brownfield grinding units by Sep'19, (b) the greenfield grinding unit in Aligarh by Dec'19 and in Gujarat by Mar'20. (2) Taking various initiatives to improve profitability, JKCE has achieved savings of INR50/t in FY19 via logistics optimization and INR250m via AFR usage. (3) The company has guided for growth 10-12% in the grey cement business and ~10% in the white cement business in FY20.
- Valuation view: JKCE's capacity expansion will reduce the proportion of inefficient assets. JKCE is strategically well placed to benefit price improvement in the north due to limited supply addition. The white cement business has gained meaningful scale and deserves premium valuations, given raw material scarcity and JKCE's 40-45% share in the domestic white cement market. We value the white cement business at 10x, grey cement at 8x and Fujairah at 6x FY21E EV/EBITDA to arrive at a TP of INR1155. Buy.

Quarterly Periormance (Standarone)											(IIAL IA	/IIIIIOII)
Y/E March		FY18	3	FY19				FY19			FY19	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Sales Dispatches (m ton)	2.13	2.22	2.32	2.72	2.32	2.16	2.50	2.88	9.39	9.88	2.87	0

Sales Dispatches (m ton)	2.13	2.22	2.32	2.72	2.32	2.16	2.50	2.88	9.39	9.88	2.87	0
YoY Change (%)	12.7	15.8	21.0	26.4	8.9	-2.9	7.5	5.8	19.1	5.1	5.4	
Realization (INR/ton)	4,900	4,981	4,847	4,839	4,819	5,096	5,098	5,182	4,888	5,044	5,142	1
YoY Change (%)	3.2	3.7	2.3	1.3	-1.7	2.3	5.2	7.1	2.7	3.2	6.3	
QoQ Change (%)	2.6	1.6	-2.7	-0.2	-0.4	5.8	0.0	1.7			0.9	
Net Sales	10,415	11,077	11,261	13,160	11,156	11,006	12,732	14,919	45,912	49,813	14,744	1
YoY Change (%)	16.4	20.1	23.7	28.0	7.1	-0.6	13.1	13.4	22.3	8.5	12.0	
Total Expenditure	8,438	9,005	9,559	11,343	9,652	9,309	10,627	12,124	38,309	41,712	11,891	2
EBITDA	1,977	2,072	1,702	1,816	1,504	1,698	2,105	2,795	7,604	8,101	2,853	-2
Margins (%)	19.0	18.7	15.1	13.8	13.5	15.4	16.5	18.7	16.6	16.3	19.4	
Depreciation	450	492	451	470	474	487	486	497	1,863	1,944	496	0
Interest	680	633	578	562	547	583	564	533	2,454	2,221	570	-6
Other Income	186	220	249	533	158	180	118	349	1,153	799	174	101
PBT before EO expense	1,033	1,167	923	1,317	640	808	1,173	2,114	4,440	4,736	1,961	8
Extra-Ord expense	0	-58	1	91	0	0	0	0	34	0	0	
PBT	1,033	1,225	922	1,227	640	808	1,173	2,114	4,406	4,736	1,961	8
Tax	240	293	193	265	147	161	564	614	991	1,487	502	22
Rate (%)	23.2	23.9	20.9	21.6	22.9	20.0	48.1	29.1	22.5	31.4	25.6	
Reported PAT	793	931	729	962	493	647	609	1,500	3,415	3,249	1,458	3
Adj PAT	793	873	731	1,052	493	647	609	1,500	3,449	3,249	1,458	3
YoY Change (%)	13 1	113 5	10 9	130.2	-37.8	-25 9	-16.6	42 5	49 9	-5.8	38.6	



BSE SENSEX	S&P CNX
38,970	11,709
Bloomberg	INDOSTAR IN
Equity Shares (m)	92
M.Cap.(INRb)/(USDb)	32.8 / 0.5
52-Week Range (INR)	607 / 275
1, 6, 12 Rel. Per (%)	-12/-10/-52
12M Avg Val (INR M)	100
Free float (%)	39.5

Financials & Valuations (INR b)

Y/E March	2019	2020E	2021E
NII	5.2	9.0	12.1
Total Income	6.4	10.8	14.0
PPoP	4.0	6.8	9.3
PAT	2.4	3.5	4.9
EPS (INR)	26.1	38.4	53.5
EPS Gr. (%)	3	47	39
BV (INR)	326	367	422
BVPS Gr. (%)	24	13	15
RoA (%)	2.5	2.4	2.5
RoE (%)	9.5	11.1	13.6
Payout (%)	0.0	0.0	0.0
Valuations			
P/E (x)	13.8	9.3	6.7
P/BV (x)	1.1	1.0	0.8

Indostar Capital Finance

TP: INR525 (+48%) **CMP: INR356** Buy

Steady quarter; Acquisition of IIFL's CV financing business complete

- 4QFY19 PAT increased 83% YoY to INR741m, driven by healthy NII growth, higher upfronting of assignment income and controlled opex.
- The company completed the INR35.2b (INR22.4b on-book) acquisition of IIFL's CV financing business on 31st Mar'19, resulting in goodwill of ~INR3b. Excluding the acquisition, total AUM grew 8% QoQ to INR83.7b, largely driven by the VF portfolio.
- Disbursements in corporate finance rebounded from INR3-4b in the past two quarters to INR12b in 4QFY19, due to a structured finance deal of ~INR6b for a stressed asset. INDOSTAR sold down INR3-4b and retained INR2.5b on its books. In the vehicle finance business too, disbursements improved from INR3.5b to INR5.8b QoQ.
- NII declined 10% QoQ to INR1.27b, driven by a sharp 11% QoQ increase in interest expenses as incremental cost of funds rose to 10-10.5%.
- GNPL ratio jumped 170bp sequentially to 2.6% due to the IIFL book acquisition (GNPL ratio of ~9%). However, management expects net credit loss of 100-150bp on a run-rate basis for the combined VF book.
- For FY19, PAT grew 20% YoY to INR2.4b, while RoE remained largely stable at 9.5%.

Valuation and view: INDOSTAR is at the beginning of its 'second innings' – the ongoing business diversification into retail lending will help drive growth, improve credit rating and enable it to enjoy higher leverage. While RoE is likely to be subdued at 10-11% in the near term, it is likely to improve to 13-15% over the medium term. With capital adequacy ratio of 20%+, it is well capitalized and will not require any further dilution over the medium term. The key risk to our thesis lies in continued liquidity tightness leading to lowerthan-expected growth in the vehicle finance segment. We maintain our estimates. Buy with TP of INR525 (1.2x FY21 BVPS).

INDOSTAR: Quarterly Performance									(II	NR Million)
Y/E March			FY19				FY2018	FY2019		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Interest Income	1,813	1,970	2,069	2,036	2,234	2,786	2,886	2,907	7,631	10,813
Interest Expenses	766	740	781	968	1,119	1,404	1,474	1,639	3,256	5,636
Net Interest Income	1,047	1,230	1,288	1,068	1,115	1,382	1,411	1,268	4,376	5,177
YoY Growth (%)					6.5	12.4	9.6	18.8		18.3
Other Income	22	25	-247	106	17	412	311	504	258	1,244
Total Income	1,069	1,255	1,041	1,174	1,132	1,794	1,722	1,772	4,634	6,420
YoY Growth (%)					5.9	43.0	65.5	51.0		38.6
Operating Expenses	298	306	438	506	541	692	580	654	1,547	2,466
Operating Profit	771	949	603	668	591	1,102	1,142	1,118	3,086	3,954
YoY Growth (%)					-23.4	16.2	89.5	67.4		28.1
Provisions & Loan Losses	-17	-119	23	-21	77	111	48	-73	-38	163
Profit before Tax	788	1,068	580	689	514	992	1,094	1,192	3,124	3,792
Tax Provisions	277	373	186	285	200	352	381	451	1,122	1,384
Net Profit	511	695	394	404	315	640	713	741	2,003	2,408
YoY Growth (%)					-38.3	-7.9	80.7	83.4		20.2
AUM Growth (%)					23.3	4.0	(0.2)	51.5	18.6	89.1
NIM (%)		10.5	10.9	7.7	6.6	7.3	7.3	5.2	7.9	6.4
Cost to Income Ratio (%)	27.8	24.4	42.1	43.1	47.8	38.6	33.7	36.9	33.4	38.4
Tax Rate (%)	35.2	35.0	32.0	41.4	38.8	35.5	34.9	37.8	35.9	36.5

^{*}Quarterly and annual numbers may not match due to different reporting formats

22 May 2019 11







Va Tech Wabag

 BSE SENSEX
 S&P CNX

 38,970
 11,709

CMP: INR309 TP: INR351 (+14%)

Neutral

Conference Call Details



Date: 22nd May 2019 Time: 4:00pm IST Dial-in details: +91-22-62801256

Financials & Valuations (INR b)

		- /	
Y/E March	2019	2020E	2021E
Net Sales	27.8	44.9	55.0
EBITDA	2.2	3.9	4.8
NP	1.3	2.1	2.6
EPS (INR)	23.1	39.0	48.0
EPS Gr. (%)	-9.4	68.5	23.1
BV/Sh. (INR)	222.7	254.6	293.8
RoE (%)	9.5	16.4	17.5
RoCE (%)	8.0	13.7	14.7
P/E (x)	11.9	7.1	5.7
Div. Yield	1.3	2.2	2.8

Operating perf. below expectations due to weak execution

- Sales stood at INR6.8b (-35% YoY), meaningfully below our estimate of INR13.8b, attributed to lower-than-estimated overseas revenue. Overseas revenue declined 42% YoY to INR4.5b as new overseas projects are yet to pick up execution momentum. FY19 sales declined 20% YoY to INR27.8b, below management's guidance of INR35b.
- EBIDTA stood at INR473m (-53% YoY), impacted by operating deleverage, below our estimate of INR1.3b.
- EBIDTA margin stood at 7% (-270bp YoY), below our estimate of 9.1%.
- Interest cost stood at INR240m (+52% YoY), above our estimate of INR185m, given an increase in working capital requirement.
- Tax write-back of INR186m boosted reported PAT. Reported PAT stood at INR408m (-28% YoY).
- Adj. PAT (adjusted for forex loss of INR64m) stood at INR472m (+28% YoY),
 40% below our estimate.
- Trade receivables from AP Genco stands elevated at INR4.2b.
- For FY19, order inflow stood at INR48.8b (+53% YoY) and order backlog at INR86b (+26% YoY).

Quarterly Performance Consol. (INR M) FY18 FY19 FY18 FY19 FY18 FY19 Var.

		FY:	18			FY1	.9		FY18	FY19	FY19	Var.
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4Q	VsEst
Sales	6,686	8,865	8,647	10,375	6,879	7,520	6,619	6,793	34,573	27,810	13,783	-50.7%
Change (%)	15.2	14.0	20.4	-8.3	2.9	-15.2	-23.5	-34.5	7.8	-19.6	32.8	
EBITDA	405	827	757	1,010	646	498	539	473	2,999	2,155	1,250	-62.2%
Change (%)	47.5	41.4	-4.7	-23.3	59.3	-39.8	-28.8	-53.2	1.1	-28.1	31.8	
As of % Sales	6.1	9.3	8.8	9.7	9.4	6.6	8.1	7.0	8.7	7.8	9.1	
Depreciation	45	45	43	45	43	42	41	42	178	168	49	
Interest	133	143	142	158	148	177	187	240	577	753	185	
Other Income	20	2	8	26	7	5	5	27	57	44	31	
PBT	246	642	579	832	461	284	316	218	2,300	1,278	1,047	-79.2%
Tax	160	220	248	145	101	141	149	-186	774	204	325	
Effective Tax Rate (%)	64.9	34.3	42.9	17.5	21.9	49.8	47.1	(85.5)	33.7	16.0	31.0	
Minority Int	15.6	35.7	50.5	28.6	(3.9)	(85.6)	(33.7)	(68.1)	130	(191.3)	47.6	
Adj PAT	71	386	281	658	364	228	201	472	1,396	1,265	675	-30.1%
Change (%)	36.4	57.8	(1,196.1)	(13.0)	414.1	(40.8)	(28.4)	(28.3)	35.7	(9.4)	13.1	
Extra-ordinary Items	-13.0	52.0	-20.0	62.0	234.0	-130.0	46.0	64.0	81.0	214.0	0.0	
Reported PAT	84	334	301	596	130	358	155	408	1,315	1,051	675	-39.5%
Change (%)	61.5	57.5	-1,196.1	-13.0	414.1	-40.8	-28.4	-28.3	28.4	(20.1)	13.1	



Sanghi Industries

S&P CNX
11,709
SNGI IN
251
15.6 / 0.2
103 / 51
-2/-12/-49
17
34.3

Financials & Valuations (INR b)

Y/E Mar	2019	2020E	2021E
Net Sales	10.6	12.4	16.7
EBITDA	1.5	2.1	3.1
PAT	0.5	0.8	0.8
EPS (INR)	2.1	3.4	3.3
Gr. (%)	-43.6	61.3	-1.0
BV/Sh (INR)	65.8	69.1	82.7
RoE (%)	3.2	5.0	4.7
RoCE (%)	4.7	4.8	5.8
P/E (x)	30.1	18.7	18.9
P/BV (x)	1.0	0.9	0.8
EV/EBITDA (x)	14.1	13.0	8.1
P/BV (x)	1.0	0.9	0.8

Estimate change	1
TP change	1
Rating change	—

CMP: INR62 TP: INR78(+25%) Buy

EBITDA beat on lower-than-estimated cost; expansion plans on track

- **Healthy growth in volumes:** 4QFY19 volumes increased 14% YoY to 0.71mt as sales improved in Maharashtra. Realization declined 5%YoY to INR3,903/t; this resulted in revenues of INR2.7b (+9% YoY) (in-line).
- EBITDA/t declines marginally: Unitary cost decreased 5% YoY to INR3,252/t (our est. INR 3,543/t) due to savings in freight cost/t and power & fuel cost/t. However, due to weaker realizations, EBITDA/t decreased 2% YoY to INR651, with EBITDA up 12% YoY at INR460m (our est. INR381m). Depreciation was lower by INR45.2m as the company changed the useful life of Plant & Machinery and the residual value, effective 1st Jan'19. PAT increased 42% YoY to INR264m (our est. INR40m).
- Management commentary: (1) Raw material cost in 4QFY19 was higher due to clinker purchase at higher prices. Also, proportion of blended cement increased to 36% in 4QFY19 v/s 31% in 4QFY18, as a result of which higher cost of fly ash was incurred. (2) Lignite constituted 25% and coal constituted 75% of the fuel mix. (3) The company's expansion program is on track; 85-90% of the ordering is done; 70% of the civil work has been completed.
- **FY19 performance:** Volumes grew 9.5% YoY and sales increased 3.4% YoY to INR 10.6b. EBITDA/PAT declined 29%/44% YoY to INR 1.5b/INR526m.
- Valuation view: For FY20/FY21, we reduce our EBITDA estimate by 2%/8% due to lower volume and realization growth assumption. We also reduce our estimate for depreciation expense to account for the revision in useful life of PPE. As a result, upgrade in PAT estimate is 48%/39% for FY20/21. We value the stock at EV/t of USD50 (not on EV/EBITDA as FY20/21 does not capture the full benefit of capacity added in Mar'20, but does fully capture debt) to on FY21 capacity to arrive at a TP of INR78. Buy.

Standalone - Quarterly Perf.										(INR Milli	on)
Y/E March		FY1	FY18 FY19				FY18	FY19	FY19	Var.		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Sales Dispatches (m ton)	0.67	0.48	0.74	0.62	0.67	0.62	0.66	0.71	2.44	2.67	0.68	4%
YoY Change (%)	(6.5)	(16.0)	(11.4)	(20.1)	0.5	29.4	(10.8)	14.0	(15.6)	9.5	9.9	
Realization (INR/ton)	4,324	4,292	3,758	4,091	4,114	3,937	4,007	3,903	4,209	3,974	4,102	-5%
YoY Change (%)	13.6	18.1	16.0	28.7	(4.8)	(8.3)	6.6	(4.6)	21.9	(5.6)	0.3	
QoQ Change (%)	36.0	(0.7)	(12.4)	8.9	0.6	(4.3)	1.8	(2.6)			2.4	
Net Sales	2,875	2,056	2,796	2,536	2,748	2,441	2,661	2,760	10,264	10,610	2,796	-1%
YoY Change (%)	6.2	-0.8	2.8	2.8	-4.4	18.7	-4.8	8.8	2.9	3.4	10.2	
EBITDA	661	467	618	413	434	324	321	460	2,158	1,540	381	21%
Margins (%)	23.0	22.7	22.1	16.3	15.8	13.3	12.1	16.7	21.0	14.5	13.6	
Depreciation	178	180	181	185	195	198	187	134	724	713	200	
Interest	187	189	173	173	123	167	147	136	721	573	198	
Other Income	21	11	57	131	83	61	55	74	220	273	57	
PBT before EO expense	316	109	322	186	199	20	43	264	933	526	40	561%
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	316	109	322	186	199	20	43	264	933	526	40	561%
Tax	0	0	0	0	0	0	0	0	0	0	0	
Rate (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Reported PAT	316	109	322	186	199	20	43	264	933	526	40	561%
Adj PAT	316	109	322	186	199	20	43	264	933	526	40	
YoY Change (%)	32.9	28.4	596.7	-29.2	-37.1	-82.1	-86.6	42.1	47.8	-43.6	-78.5	
Margins (%)	11.0	5.3	11.5	7.3	7.2	0.8	1.6	9.6	9.1	5.0	1.4	



Telecom

RJio — the only player to add active subs in Mar'19

Bharti's MBB market share stabilizing

The Telecom Regulatory Authority of India (TRAI) has released subscriber data for the month of Mar'19. Key highlights:

- Net active subscriber base stood flat MoM at 1,022m. Bharti reported flat MoM active subs while Vodafone Idea lost 9.1m active subs. RJio continued its strong momentum, gaining 8.0m active subscribers in Mar'19.
- RJio's strong gains could be attributed to the series of Jiophone offtake. Bharti and Vodafone Idea — both are potentially witnessing an impact from the rollout of minimum recharge plans on pan-India basis.
- Broadband subscriber adds stood robust at 12.8m (+10.2m in Feb'19), reaching 544m (53% of active subscriber base).
- RJio continued to take the lion's share in incremental MBB adds (80% share among the top-3 players). However, we estimate it at 63% (ex-Jiophone), while Bharti gained ~20% share.

RJio – only telco to add active subs

Net active subscriber base remains flat MoM

Active subscriber base for the industry in Mar'19 was flat MoM at 1,022m (v/s Feb'19). RJio continued its strong active subscriber growth with 8m active subscriber adds (gaining healthy 80bp market share); Bharti's active subscriber base/market share stood flat MoM. Vodafone Idea lost 9.1m active subscribers, potentially due to the implementation of minimum ARPU plans; market share was down 90bp MoM. Overall, gross subscriber base declined 2% to 1,162m.

Bharti's active subscriber base/market share flat MoM

After witnessing a decline for three consecutive months, Bharti reported flat monthly active subscriber base at 328m; market share was also flat MoM at 32.1%. This could be attributed to the implementation of minimum ARPU plans on pan-India basis. However, gross subscriber base declined by 15m MoM (flat in Feb'19) to 325m.

RJio adds 8m active subscribers with healthy 80bp market share expansion

RJio remained the only telco to add active subscribers; it added 8m (+9.3m in Feb'19) active subs. Market share expanded 80bp MoM to 25.2%. However, it has decelerated from its six-month average of 8.6m. We believe $^{\sim}50\%$ of the addition could be attributed to Jiophone. Further, RJio added 9.5m gross subscribers on MoM basis.

Vodafone Idea sees 9.1m decline in active subscriber base; loses 90bp share

Vodafone Idea continued to lose active subscribers for almost 11 consecutive months. It lost 9.1m (-7.2m in Feb'19) active subscribers; with a 90bp MoM market share contraction to 36%. Vodafone Idea is losing ground potentially due to (a) implementation of minimum ARPU plans, and (b) deteriorating network quality possibly due to network integration issues. VIL cumulatively lost ~400bp active subscriber market share over the last one year. It lost 14.5m (-5.8m in Feb'19) gross subscribers on MoM basis.





CMP: INR133

Ashoka Buildcon

Buy

Bloomberg	ASBL IN
Equity Shares (m)	280.7
M. Cap. (INR b)/(USD b)	37 / 1
52-Week Range (INR)	197 / 93
1,6,12 Rel Perf. (%)	2 / 18 / -39

Y/E March	2018	2019E	2020E	2021E
Net Sales	24.5	34.7	47.9	57.5
EBITDA	2.9	4.5	6.0	7.2
Adj. PAT	2.4	3.0	3.5	4.2
Adj. EPS (INR)	8.4	10.6	12.4	15.1
EPS Gr (%)	34.6	25.6	16.8	21.7
BV/Sh (INR)	68.6	79.5	90.4	103.6
RoE (%)	13.0	14.3	14.6	15.5
RoCE (%)	14.0	16.1	16.7	17.6
Valuations				
P/E (x)	15.8	12.5	10.7	8.8
P/BV (x)	1.9	1.7	1.5	1.3
EV/EBITDA (x)	12.7	8.2	6.1	4.8
Div. Yield (%)	1.5	1.1	0.8	0.6

We expect revenue growth of 37% YoY, led by a pick-up in execution of orders in hand. Revenue growth will be supported by execution of the existing EPC road project portfolio and power T&D projects.

- We expect operating margin to contract 80bp YoY to 12.3% and operating profit to improve 46% YoY to INR1.2b.
- Other income is expected to be INR201m, as against INR612m in 4QFY18.
- Tax rate during the quarter is expected to be 16%, as against 9.3% in 4QFY18.
- Net profit is expected to decline 24% YoY to INR800m, given the likely fall in other income during the quarter. Maintain **Buy.**

Key issues to watch

- Equity contribution arrangement from ABL for the recently won HAM projects.
- Execution timelines for the recently won HAM projects.

Quarterly performance (INR m)

Y/E March	FY18 FY19									
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE	FY18	FY19
Net Sales	7,063	3,787	6,589	7,023	6,837	7,644	10,651	9,606	24,464	34,739
YoY Change (%)	50.8	-14.5	25.7	15.1	-3.2	101.9	61.6	36.8	19.6	42.0
Total Expenditure	6,138	3,331	5,844	6,216	6,025	6,607	9,164	8,427	21,529	30,223
EBITDA	925	456	746	807	813	1,037	1,487	1,179	2,935	4,516
Margins (%)	13.1	12.0	11.3	11.5	11.9	13.6	14.0	12.3	12.0	13.0
Depreciation	113	130	144	144	136	166	202	205	532	708
Interest	129	116	128	113	171	130	239	224	485	764
Other Income	92	108	166	612	366	157	254	201	978	978
PBT before EO expense	774	318	640	1,163	871	899	1,301	951	2,895	4,022
Extra-Ord expense	0	0	0	0	0	0	398	0	0	-398
PBT	774	318	640	1,163	871	899	903	951	2,895	3,624
Tax	205	41	170	109	232	278	281	151	524	942
Rate (%)	26.5	13.0	26.5	9.3	26.7	30.9	31.2	15.8	18.1	26.0
Reported PAT	569	277	470	1,054	639	621	622	800	2,371	2,682
Adj PAT	569	277	470	1,054	639	621	895	800	2,371	2,956
YoY Change (%)	84.7	-39.0	9.9	61.2	12.3	124.4	90.5	-24.1	28.6	24.6
Margins (%)	8.1	7.3	7.1	15.0	9.3	8.1	8.4	8.3	9.7	8.5





CMP: INR133

Bank of Baroda

Bloomberg	BOB IN
Equity Shares (m)	2,651.8
M. Cap. (INR b)/(USD b)	353 / 5.0
52-Week Range (INR)	157 / 91
1,6,12 Rel Perf. (%)	15 / 21 / -24

Financia	l Snapshot	(INRb)
----------	------------	--------

Y/E March	FY18	FY19E	FY20E	FY21E
NII	155.2	185.3	214.1	246.0
ОР	120.1	132.1	153.2	180.6
NP	-24.3	20.8	39.3	63.5
NIM (%)	2.3	2.6	2.7	2.6
EPS (INR)	-9.8	7.8	14.8	23.9
EPS Gr. (%)	NM	NM	89.0	61.4
BV/Sh. (INR)	157.1	163.8	177.5	198.6
ABV/Sh. (INR)	90.9	114.6	135.4	159.9
RoE (%)	-5.8	4.7	8.4	12.3
RoA (%)	-0.3	0.3	0.5	0.7
Valuations				
P/E(X)	-13.6	17.0	9.0	5.6
P/BV (X)	0.8	0.8	0.8	0.7
P/ABV (X)	1.5	1.2	1.0	0.8

We expect loan book to grow at 11% YoY and deposit growth to remain moderate at 7% YoY. We expect drill-down in the

- international book to continue and the focus to remain on granular retail loans.
- We expect margins to improve to 2.8% on account of re-pricing of loans and an improvement in international margins.
- We expect slippages to moderate (0.6% annualized) and GNPA/NNPA to decline to 10.9%/3.6%.
- Management aims to develop more sustained fee income streams, which, coupled with an improvement in treasury performance, is expected to result in an uptick in other income.
- PAT is expected to be at INR6.6b v/s INR4.7b in 3QFY19. PAT for FY19 is expected to be INR20.8b. The stock trades at 0.8x FY21E ABV. Buy.

Key issues to watch for

- Movement of the watch-list and stress addition from the exposure toward infra group and international book.
- Developments on the merger front and the possible benefits from the same.

(INR m) **Quarterly Performance FY18** FY19E **FY18** FY19E **1Q 2Q 3Q 4Q 1Q 2Q 3Q** 4QE 34,050 43,940 40,023 49,097 **Net Interest Income** 37,205 43,811 44,925 47,432 1,55,218 1,85,265 % Change (YoY) 1.0 8.6 40.2 11.7 28.7 20.7 7.9 22.7 14.9 19.4 17,371 16,046 66,572 57,251 Other Income 16,730 16,959 16,211 15,512 11,478 13,516 **Total Income** 49,561 54,576 60,671 56,982 55,289 58,441 63,644 65,143 2,21,789 2,42,516 **Operating Expenses** 23,080 24,158 24,170 30,327 25,233 27,622 28,258 29,346 1,01,734 1,10,459 **Operating Profit** 26,481 30,418 36,501 26,655 30,056 30,819 35,385 35,797 1,20,056 1,32,057 % Change (YoY) -0.8 13.1 40.6 -11.7 13.5 1.3 -3.1 34.3 9.4 10.0 26,143 Provisions 23,681 23,294 34,265 66,724 21,656 24,295 27,942 1,47,963 1,00,037 **Profit before Tax** 2,801 7,125 2,236 -40,069 8,400 6,524 7,443 9,654 -27,907 32,020 Tax 767 3,571 1,118 -9,046 3,120 2,270 2,731 3,086 -3,589 11,207 **Net Profit** 2,034 3,554 1,118 -31,023 5,280 4,254 4,712 6,567 -24,318 20,813 % Change (YoY) -52.0 -35.6 -55.8 159.6 19.7 321.6 NM NM NM NM **Operating Parameters** 5,706 5,913 5,815 6,070 Deposit (INR b) 5.832 5,733 6,106 6.327 5.913 6.327 Loan (INR b) 3,776 3,873 3,994 4,274 4,145 4,335 4,487 4,727 4,274 4,727 **Asset Quality** Gross NPA (INR B) 462 463 485 565 559 551 532 516 565 516 Gross NPA (%) 11.4 11.2 11.3 12.3 12.5 11.8 11.0 10.9 12.3 10.9 170.2 Net NPA (INR B) 195.2 195.7 198.5 234.8 223.8 210.6 191.3 170.2 234.8 Net NPA (%) 4.9 5.2 5.0 5.5 5.4 4.3 3.6 5.5 3.6 5.1 57.7 59.9 67.0 58.4 PCR (%) 57.7 59.1 58.4 61.8 64.0 67.0

22 May 2019 16





Cipla

Bloomberg	CIPLA IN
Equity Shares (m)	804.5
M. Cap. (INR b)/(USD b)	423 / 6
52-Week Range (INR)	678 / 484
1,6,12 Rel Perf. (%)	-13 / -27 / -26

Y/E MARCH	2018	2019E	2020E	2021E
Sales	152.2	160.7	178.7	199.9
EBITDA	28.3	28.6	33.7	39.1
NP	16.3	14.1	17.1	20.3
EPS (INR)	20.3	17.6	21.2	25.3
EPS Gro. (%)	31.2	-13.6	20.8	19.1
BV/Sh. (INR)	176.7	191.3	209.5	231.7
RoE (%)	11.5	9.2	10.1	10.9
RoCE (%)	8.6	7.8	8.9	9.7
Valuations				
P/E (x)	25.8	29.9	24.7	20.8
P/BV (x)	3.0	2.7	2.5	2.3
EV/EBITDA (x)	16.0	15.8	13.1	11.2
EV/Sales (x)	3.0	2.8	2.5	2.2

CMP: INR526 Neutral

- We expect Cipla's revenue to grow ~11% YoY to INR41b in 4QFY19.
- Growth is expected to be driven by domestic formulations business which we expect to grow by 21% YoY. Export formulations are expected to grow at a subdued rate of 5% YoY on account of decline in sales expected in South Africa and emerging markets. This decline will be somewhat offset by exports to the US (which are expected to deliver strong growth of 31% YoY) and EU (which are expected to grow by 8% YoY).
- EBITDA margin is expected to come in at 17.6% (+250bp YoY).
 Absolute EBITDA is expected to see 30% YoY growth to INR7.2b.
- We expect PAT to grow 1% YoY to INR3.4b on account of increased tax rate during the quarter (25.8% vs 16.7% in 4QFY18).
- We remain positive on the company on the back of outperformance in domestic formulations business and better traction in the US business leveraging on its own front end. However, we maintain **Neutral**.

Key issues to watch out for

- > Quality of filings in US and approval rate.
- Response to USFDA latest inspection observations.
- Outlook on institutional business.
- > New product launches in the domestic segment.

(INR m)

Y/E March	FY18 FY19E				FY18	FY19E				
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Net Revenues	35,251	40,824	39,139	36,980	39,390	40,119	40,075	41,085	152,200	160,669
YoY Change (%)	-3.4	8.8	7.3	3.2	11.7	-1.7	2.4	11.1	4.3	5.6
EBITDA	6,465	8,044	8,187	5,569	7,264	7,022	7,077	7,237	28,271	28,599
Margins (%)	18.3	19.7	20.9	15.1	18.4	17.5	17.7	17.6	18.6	17.8
Depreciation	2,134	3,022	5,224	2,848	2,410	2,819	2,931	2,854	13,228	11,014
Interest	279	420	92	352	351	444	442	362	1,142	1,598
Other Income	1,514	1,133	529	400	551	1,326	785	688	3,577	3,350
Profit before Tax	5,566	5,735	3,402	2,769	5,056	5,085	4,489	4,710	17,477	19,337
Extra-Ord (expense)/income	0	0	0	775	1,150	0	0	0	775	1,150
PBT after EO expense	5,566	5,735	3,402	1,994	6,206	5,085	4,489	4,710	16,702	20,487
Tax	1,308	1,374	-642	462	1,737	1,424	1,257	1,216	2,501	5,634
Rate (%)	23.5	24.0	-18.9	16.7	34.4	28.0	28.0	25.8	14.3	29.1
Minority Interest	169.6	134.7	38.1	-254.2	-45.7	-109.2	-90.0	124.9	88.2	-120.0
Reported PAT	4,088	4,226	4,006	1,786	4,515	3,770	3,322	3,369	14,113	14,973
Adj PAT	4,088	4,226	4,677	3,336	3,655	3,770	3,322	3,369	16,335	14,116
YoY Change (%)	20.6	19.3	24.8	64.2	-10.6	-10.8	-29.0	1.0	31.2	-13.6
Margins (%)	11.6	10.4	12.0	9.0	9.3	9.4	8.3	8.2	10.7	8.8





Cummins India

Bloomberg	KKC IN
Equity Shares (m)	277.2
M. Cap. (INR b)/(USD b)	206 / 3
52-Week Range (INR)	885 / 612
1,6,12 Rel Perf. (%)	-3 / 4 / -13

Einancial	Spanchot	(IND P)

Y/E March	2018	2019E	2020E	2021E
Net Sales	50.8	56.7	65.7	72.9
EBITDA	7.3	9.3	11.5	12.8
Adj. PAT	6.5	7.6	9.1	10.0
EPS (INR)	23.5	27.3	32.8	36.2
EPS Gr. (%)	-11.2	16.2	20.1	10.3
BV/Sh. (INR)	143.8	155.3	169.2	184.4
RoE (%)	18.3	18.3	20.2	20.5
RoCE (%)	16.1	17.5	19.4	19.7
Payout (%)	58.7	49.7	49.7	49.7
Valuations				
P/E (x)	35.9	30.9	25.8	23.4
P/BV (x)	5.9	5.4	5.0	4.6
EV/EBITDA (x)	31.7	24.4	19.8	17.6
Div Yield (%)	1.8	1.6	1.9	2.1

CMP: I	NR745		Buy

- We expect revenue to increase 7% YoY, supported by growth in the Industrial segment (24% YoY) and Distribution and Spars business (+17% YoY). However, exports is expected to decline sharply (-18% YoY) given weak demand from Middle East and Europe.
- EBITDA margin is expected to remain flat YoY to 14%; and operating profit is expected to improve 8% YoY to INR1.9b.
- Net profit is expected to register growth of 3% YoY to INR1.7b. Maintain Buy.

Key issue to watch

> Performance and guidance for the exports segment

Quarterly Performance (INR m)

		FY1	8			FY1	9		FY18	FY19
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Sales	13,408	11,539	13,547	12,332	13,280	14,869	15,038	13,134	50,825	56,427
Change (%)	6.5	-9.8	0.0	4.1	-1.0	28.9	11.0	6.5	0.1	11.0
EBITDA	1,953	1,675	1,967	1,731	2,147	2,509	2,267	1,870	7,325	8,899
Change (%)	-5.4	-15.8	-13.2	1.8	9.9	49.8	15.3	8.0	-12.3	27.7
As of % Sales	14.6	14.5	14.5	14.0	16.2	16.9	15.1	14.2	14.4	15.8
Depreciation	208	220	237	273	271	274	279	287	938	1,111
Interest	42	38	34	34	36	40	41	32	148	148
Other Income	583	536	501	664	696	785	755	814	2,285	3,050
PBT	2,286	1,953	2,197	2,088	2,536	2,980	2,702	2,365	8,523	10,690
Tax	625	424	475	475	706	865	831	698	2,000	3,100
Effective Tax Rate (%)	27.4	21.7	21.6	22.8	27.8	29.0	30.8	29.5	23.5	29.0
Adjusted PAT	1,660	1,529	1,722	1,612	1,830	2,116	1,871	1,667	6,524	7,590
Change (%)	(8.4)	(22.3)	(13.1)	1.7	10.2	38.4	8.7	3.4	(11.2)	16.4
Extra-ordinary Income (net)	561.2	-	-	-	-	-	-	-	561.2	2.6
Reported PAT	2,222	1,529	1,722	1,612	1,830	2,116	1,871	1,667	7,085	7,593
Change (%)	22.6	(22.3)	(13.1)	1.7	(17.6)	38.4	8.7	3.4	(3.6)	7.2





Future Consumer

Bloomberg	FCON IN
Equity Shares (m)	1902.1
M. Cap. (INR b)/(USD b)	85 / 1
52-Week Range (INR)	63 / 35
1,6,12 Rel Perf. (%)	-14 / 9 / -37

52-Week Range (INR)	
1,6,12 Rel Perf. (%)	-

Financial Snapshot (INR b)							
Y/E March	2018	2019E	2020E	2021E			
Sales	30.1	38.6	51.7	68.7			
EBITDA	0.5	1.0	2.3	4.1			
NP	-0.3	-0.2	1.1	2.7			
EPS (INR)	-0.2	-0.1	0.7	1.6			
EPS Gr. (%)	-53.2	-39.9	-715.4	136.0			
BV/Sh. (INR)	6.0	5.9	6.6	8.2			
RoE (%)	-3.3	-1.9	11.0	21.9			
RoCE (%)	2.2	4.6	10.9	17.4			
Valuations							
P/E (x)	-240.6	-400.1	65.0	27.5			
P/BV (x)	7.4	7.5	6.8	5.4			
EV/Sales (x)	146.8	80.2	35.9	19.5			
EV/EBITDA (x)	2.6	2.1	1.6	1.2			

CMP: INR45	Buy
------------	-----

- We expect Future Consumer's (FCON) sales to grow 25.9% YoY to INR10.2b.
- Gross margins are expected to remain flat YoY at 12.9% (up 10bp
- We estimate EBITDA margin expansion of 70bp YoY to 2.8% (up just 10bp QoQ). Hence, we have modeled EBITDA growth of 71.9% in the quarter with adj. loss of INR41m.
- The stock trades at 1.6x/3.1x FY20E/21E EV/sales. **Buy**.

Key issues to watch for

- Whether the pace of top-line growth will be sustained.
- > Extent of gross margin expansion.
- > Flow of gross margin expansion into EBITDA margin.
- Commentary on working capital

Consolidated - Quarterly Earning Model

Y/E March		FY18	3			FY1	9		FY18	FY19E
_	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Sales	6,626	7,510	7,847	8,075	8,409	10,111	9,912	10,169	30,050	38,602
YoY Change (%)	41.9	33.2	42.3	51.4	26.9	34.6	26.3	25.9	42.0	28.5
Gross Profit	922	1,038	1,071	1,042	1,182	1,331	1,273	1,310	4,076	5,095
Margins (%)	13.9	13.8	13.7	12.9	14.1	13.2	12.8	12.9	13.6	13.2
EBITDA	86	128	166	168	201	251	272	288	541	1,012
YoY Change (%)	949.1	318.3	420.1	543.0	133.4	96.0	64.0	71.9	458.9	87.0
Margins (%)	1.3	1.7	2.1	2.1	2.4	2.5	2.7	2.8	1.8	2.6
Depreciation	90	113	106	146	123	127	139	148	455	536
Interest	128	122	136	140	159	172	194	208	527	734
Other Income	58	52	45	163	83	89	67	77	325	317
PBT	-74	-55	-31	44	2	40	7	10	-115	60
Tax	0	0	0	-25	0	10	5	-13	-25	2
Rate (%)	0.0	0.0	0.0	-56.4	0.0	25.8	62.3	-135.3	21.7	2.9
Minority Interest & P/L of Asso. Cos.	28	33	16	110	61	60	55	64	216	240
Reported PAT	-102	-88	-47	-41	-59	-30	-52	-41	-306	-182
Adj PAT	-102	-88	-47	-41	-59	-30	-53	-41	-306	-184
YoY Change (%)	-51.0	-45.6	-66.5	-59.6	-41.8	-65.9	13.2	-0.4	Loss	LP
Margins (%)	-1.5	-1.2	-0.6	-0.5	-0.7	-0.3	-0.5	-0.4	-1.0	-0.5

E: MOFSL Estimates

22 May 2019 19





GE T&D

Bloomberg	GETD IN
Equity Shares (m)	256.1
M. Cap. (INR b)/(USD b)	74 / 1
52-Week Range (INR)	413 / 219
1,6,12 Rel Perf. (%)	-8 / 15 / -46

Financial Snapsh	ot (INR I	2)
------------------	-----------	----

	•	-		
Y/E March	2018	2019E	2020E	2021E
Net Sales	43.3	44.0	44.8	46.9
EBITDA	2.9	4.5	4.6	4.8
Adj. PAT	1.9	2.5	2.8	3.0
EPS (INR)	7.5	9.9	11.1	11.8
EPS Gr. (%)	30.8	31.9	12.1	6.7
BV/Sh. (INR)	46.5	52.6	59.5	66.8
RoE (%)	17.3	20.0	19.8	18.7
RoCE (%)	22.5	31.1	29.9	28.1
Payout (%)	31.4	31.4	31.4	31.4
Valuations				
P/E (x)	38.7	29.3	26.2	24.5
P/BV (x)	6.2	5.5	4.9	4.3
EV/EBITDA (x)	24.5	15.8	15.0	14.0
EV/ Sales (x)	1.6	1.6	1.5	1.4
Div Yield (%)	0.6	1.1	1.2	1.3

CMP: INR290 Neutral

- We expect GE T&D to register revenue growth of 32% YoY to INR10.7b in 4QFY19. Revenue growth is supported by the weak base of 4QFY18 (-32.0% YoY).
- We expect operating profit of INR1b in 4QFY19, as against INR179m in 4QFY18. Operating margins are expected to improve 740bp at normalized level of to 9.6%. Margins in 4QFY18 (2.2%) were impacted by weak execution leading to operating deleverage.
- GET&D is expected to book net profit of INR665m as against INR305m in 4QFY18. Maintain Neutral.

Key issues to watch

Progress in the Champa-Kurukshetra II project, which is expected to be executed in FY19

Quarterly Performance (INR m)

		FY1	.8			FY1	9			
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE	FY18	FY19
Sales	12,093	8,700	14,386	8,139	11,624	9,933	11,678	10,762	43,317	43,997
Change (%)	41.5	4.2	23.5	-32.0	-3.9	14.2	-18.8	32.2	6.9	1.6
EBITDA	1,055	805	728	179	1,442	921	1,126	1,030	2,853	4,519
Change (%)	4,875.9	130.6	-3.0	-83.7	36.7	14.5	54.7	475.9	-9.0	-9.0
As of % Sales	8.7	9.3	5.1	2.2	12.4	9.3	9.6	9.6	6.6	10.3
Depreciation	224	228	218	229	217	215	202	212	899	846
Interest	278	225	238	141	155	143	141	112	883	550
Other Income	422	344	630	638	192	238	97	242	1,948	769
PBT	975	695	1,099	419	1,262	801	880	949	3,189	3,893
Tax	358	220	381	141	442	287	350	284	1,101	1,362
Effective Tax Rate (%)	36.7	31.6	34.7	33.7	35.0	35.8	39.7	29.9	34.5	35.0
Reported PAT	617	475	718	278	820	515	531	665	2,088	2,530
Change (%)	-131.3	131.6	62.0	-39.7	33.0	8.3	-26.1	139.2	NM	21.2
Adj PAT	617	475	521	305	820	515	531	665	1,919	2,530
Change (%)	71.4	131.6	17.6	-33.8	33.0	8.3	1.8	117.7	30.8	31.9





IndusInd Bank

Bloomberg	IIB IN
Equity Shares (m)	602.0
M. Cap. (INR b)/(USD b)	1,069 / 15.1
52-Week Range (INR)	2,038 / 1,334
1,6,12 Rel Perf. (%)	9/1/-19

Einancial Spanchat (IND D)

Financial Snapshot (INK B)											
FY18	FY19E	FY20E	FY21E								
75.0	90.2	135.6	176.7								
66.6	82.8	125.8	161.6								
36.1	34.7	69.3	89.8								
4.2	4.0	4.7	4.8								
60.2	53.8	99.4	127.4								
25.2	-10.6	84.8	28.2								
394	427.1	541.0	656.6								
385	416.2	529.2	644.3								
16.5	13.1	20.6	21.4								
1.8	1.4	2.2	2.3								
12.0	16.4	10.5	9.2								
29.5	33.0	17.9	13.9								
4.5	4.2	3.3	2.7								
4.6	4.3	3.4	2.8								
0.4	0.5	0.6	0.7								
	FY18 75.0 66.6 36.1 4.2 60.2 25.2 394 385 16.5 1.8 12.0 29.5 4.5	FY18 FY19E 75.0 90.2 66.6 82.8 36.1 34.7 4.2 4.0 60.2 53.8 25.2 -10.6 394 427.1 385 416.2 16.5 13.1 1.8 1.4 12.0 16.4 29.5 33.0 4.5 4.2 4.6 4.3	FY18 FY19E FY20E 75.0 90.2 135.6 66.6 82.8 125.8 36.1 34.7 69.3 4.2 4.0 4.7 60.2 53.8 99.4 25.2 -10.6 84.8 394 427.1 541.0 385 416.2 529.2 16.5 13.1 20.6 1.8 1.4 2.2 12.0 16.4 10.5 29.5 33.0 17.9 4.5 4.2 3.3 4.6 4.3 3.4								

CIV	/IP: INR1,776	Buy
	We expect IIB to report strong loan growth of ~32% YoY in	

- We expect IIB to report strong loan growth of ~32% YoY in 4QFY19, significantly ahead of system loan growth. Deposit growth should also remain strong at ~22% YoY. Margins are likely to remain flattish QoQ at ~3.9%.
- We expect non-interest income to grow ~26% YoY, supported by healthy fee income growth. Stronger third-party distribution fees and treasury gains will further support non-interest income.
- Opex growth would remain at ~15% YoY v/s 22% growth in total income. PPoP growth would remain healthy at 28% YoY.
- We expect earnings to remain under pressure and report a PAT of INR5.3b in 4QFY19 (INR34.7b for FY19) on account of elevated provisions due to IL&FS.
- IIB trades at 2.8x FY21E ABV. Maintain **Buy**.

Key issues to watch for

- Impact on the CV portfolio, particularly after the slowdown in CV sales.
- Corporate asset quality will be a key monitorable.
- Provisioning and further developments on the IL&FS exposure

Quarterly Performance										(INR m)
		FY1	8			FY19	9E		FV10	EV10E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE	FY18	FY19E
Net Interest Income	17,741	18,210	18,948	20,076	21,224	22,033	22,881	24,037	74,974	90,175
% Change (YoY)	30.8	24.7	20.0	20.4	19.6	21.0	20.8	19.7	23.7	20.3
Other Income	11,673	11,876	11,868	12,085	13,016	13,173	14,689	15,174	47,501	56,051
Total Income	29,413	30,086	30,816	32,161	34,240	35,206	37,569	39,211	1,22,475	1,46,226
Operating Expenses	13,528	13,751	14,169	14,467	15,129	15,281	16,400	16,635	55,914	63,445
Operating Profit	15,885	16,335	16,647	17,694	19,111	19,924	21,170	22,576	66,561	82,781
% Change (YoY)	28.8	27.5	22.1	12.5	20.3	22.0	27.2	27.6	22.1	24.4
Provisions	3,100	2,938	2,362	3,356	3,500	5,903	6,067	14,780	11,754	30,250
Profit before Tax	12,786	13,398	14,285	14,338	15,611	14,022	15,103	7,796	54,807	52,531
Tax	4,420	4,597	4,923	4,808	5,254	4,819	5,253	2,535	18,747	17,861
Net Profit	8,365	8,801	9,362	9,531	10,357	9,203	9,850	5,261	36,060	34,671
% Change (YoY)	26.5	25.0	24.7	26.8	23.8	4.6	5.2	-44.8	25.7	-3.9
Operating Parameters										
Deposit Growth (%)	31.4	25.9	22.5	19.8	18.8	18.9	20.3	22.0	19.8	22.0
Loan Growth (%)	24.3	24.5	25.1	28.2	29.4	32.4	34.7	32.0	28.2	32.0
Deposit (INR b)	1,337	1,414	1,461	1,516	1,589	1,682	1,757	1,850	1,516	1,850
Loan (INR b)	1,164	1,232	1,285	1,450	1,507	1,631	1,732	1,913	1,450	1,913
Asset Quality										
Gross NPA (INR b)	12.7	13.5	15.0	17.0	17.4	17.8	19.7	21.2	17.0	21.2
Gross NPA (%)	1.1	1.1	1.2	1.2	1.2	1.1	1.1	1.1	1.2	1.1
Net NPA (INR b)	5.1	5.4	5.9	7.5	7.6	7.9	10.3	10.7	7.5	10.7
Net NPA (%)	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.6	0.5	0.6
PCR (%)	60.0	60.1	60.5	56.3	56.2	55.8	47.7	49.5	56.3	49.5





Quess Corp

Bloomberg	QUESS IN
Equity Shares (m)	146.1
M. Cap. (INR b)/(USD b)	108 / 2
52-Week Range (INR)	1300 / 581
1,6,12 RelPerf. (%)	-5 / -23 / -45

INR million	FY18	FY19	FY20E	FY21E
Sales	61.7	85.5	105.8	123.9
EBITDA	3.5	4.6	6.4	7.8
NP	3.1	2.5	4.5	5.9
EPS (Rs)	21.8	17.4	30.5	40.5
EPS Growth (%)	115.7	-20.2	75.2	32.7
BV/Share (Rs)	217.1	239.6	278.9	331.1
P/E (x)	32.4	40.6	23.2	17.5
P/BV (x)	3.3	3.0	2.5	2.1
EV/EBITDA (x)	29.5	22.3	16.0	12.9
EV/Sales (x)	1.7	1.2	1.0	0.8
RoE (%)	16.5	9.8	15.2	17.1
RoCE (%)	14.6	10.2	14.2	16.0

CMP: INR740 Neutral

- We expect revenue of INR23.2b for Quess in 4QFY19, signifying growth of 22.8% YoY.
- With total headcount in north at 190,000 in PS business, we expect growth of 27.5% YoY. GTS business is expected to grow at 31% YoY.
- We expect EBITDA margin to gradually increase hereon. Our estimate for EBITDA margin stands at 5.5%, which is expected to inch up by 20bp sequentially due to normalization of investments in the P&S business.
- Our PAT estimate is INR822m, a decline of 4% YoY. While benefits will come from 80JJA, we expect tax rate to normalize at 11% (vs. 4% in 4QFY18). PAT margin is 3.1% for 4QFY19.

Key things to watch for

- Integration of recently acquired entities.
- > Restructuring of operations in the industrials segment.
- Organic growth momentum and traction in the general staffing business post-GST.

Consolidated - Quarterly

	FY1	8		FY19			FY18	FY19E	
1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
12,973	13,953	15,840	18,908	19,684	20,917	21,722	23,218	61,673	85,540
30.9	37.1	48.5	52.5	51.7	49.9	37.1	22.8	42.9	38.7
12,221	13,164	14,930	17,814	18,659	19,797	20,538	21,930	58,129	80,924
752	789	909	1,093	1,025	1,120	1,183	1,287	3,544	4,616
5.8	5.7	5.7	5.8	5.2	5.36	5.4	5.5	5.7	5.4
136	144	183	285	299	291	317	317	747	1,223
170	157	177	252	261	282	280	282	755	1,107
35	168	126	240	156	143	123	134	569	556
482	656	675	797	621	690	710	822	2,611	2,841
0	0	0	0	0	0	0	0	0	0
482	656	675	797	621	690	710	822	2,611	2,841
31	-619	74	31	93	105	11	90	-483	299
6.4	-94.4	11.0	3.9	14.9	15.1	1.5	11.0	-18.5	10.5
-6	2	-9	8	-16	-31	49	5	-4	0
457	1,274	610	758	544	616	650	726	3,098	2,543
457	1,274	610	758	544	616	650	726	3,098	2,543
84.8	322.8	81.2	127.2	19.2	-51.6	6.5	-4.1	154.2	-17.9
3.5	9.1	3.9	4.0	2.8	2.9	3.0	3.1	5.0	3.0
	12,973 30.9 12,221 752 5.8 136 170 35 482 0 482 31 6.4 -6 457 457 84.8	1Q 2Q 12,973 13,953 30.9 37.1 12,221 13,164 752 789 5.8 5.7 136 144 170 157 35 168 482 656 0 0 482 656 31 -619 6.4 -94.4 -6 2 457 1,274 44.8 322.8	12,973 13,953 15,840 30.9 37.1 48.5 12,221 13,164 14,930 752 789 909 5.8 5.7 5.7 136 144 183 170 157 177 35 168 126 482 656 675 0 0 0 482 656 675 31 -619 74 6.4 -94.4 11.0 -6 2 -9 457 1,274 610 84.8 322.8 81.2	1Q 2Q 3Q 4Q 12,973 13,953 15,840 18,908 30.9 37.1 48.5 52.5 12,221 13,164 14,930 17,814 752 789 909 1,093 5.8 5.7 5.7 5.8 136 144 183 285 170 157 177 252 35 168 126 240 482 656 675 797 0 0 0 0 482 656 675 797 31 -619 74 31 6.4 -94.4 11.0 3.9 -6 2 -9 8 457 1,274 610 758 457 1,274 610 758 84.8 322.8 81.2 127.2	1Q 2Q 3Q 4Q 1Q 12,973 13,953 15,840 18,908 19,684 30.9 37.1 48.5 52.5 51.7 12,221 13,164 14,930 17,814 18,659 752 789 909 1,093 1,025 5.8 5.7 5.7 5.8 5.2 136 144 183 285 299 170 157 177 252 261 35 168 126 240 156 482 656 675 797 621 31 -619 74 31 93 6.4 -94.4 11.0 3.9 14.9 -6 2 -9 8 -16 457 1,274 610 758 544 457 1,274 610 758 544 84.8 322.8 81.2 127.2 19.2	1Q 2Q 3Q 4Q 1Q 2Q 12,973 13,953 15,840 18,908 19,684 20,917 30.9 37.1 48.5 52.5 51.7 49.9 12,221 13,164 14,930 17,814 18,659 19,797 752 789 909 1,093 1,025 1,120 5.8 5.7 5.7 5.8 5.2 5.36 136 144 183 285 299 291 170 157 177 252 261 282 35 168 126 240 156 143 482 656 675 797 621 690 31 -619 74 31 93 105 6.4 -94.4 11.0 3.9 14.9 15.1 -6 2 -9 8 -16 -31 457 1,274 610 758 544	1Q 2Q 3Q 4Q 1Q 2Q 3Q 12,973 13,953 15,840 18,908 19,684 20,917 21,722 30.9 37.1 48.5 52.5 51.7 49.9 37.1 12,221 13,164 14,930 17,814 18,659 19,797 20,538 752 789 909 1,093 1,025 1,120 1,183 5.8 5.7 5.7 5.8 5.2 5.36 5.4 136 144 183 285 299 291 317 170 157 177 252 261 282 280 35 168 126 240 156 143 123 482 656 675 797 621 690 710 31 -619 74 31 93 105 11 6.4 -94.4 11.0 3.9 14.9 15.1 1.5	1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 12,973 13,953 15,840 18,908 19,684 20,917 21,722 23,218 30.9 37.1 48.5 52.5 51.7 49.9 37.1 22.8 12,221 13,164 14,930 17,814 18,659 19,797 20,538 21,930 752 789 909 1,093 1,025 1,120 1,183 1,287 5.8 5.7 5.7 5.8 5.2 5.36 5.4 5.5 136 144 183 285 299 291 317 317 170 157 177 252 261 282 280 282 35 168 126 240 156 143 123 134 482 656 675 797 621 690 710 822 31 -619 74 31 93	1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 12,973 13,953 15,840 18,908 19,684 20,917 21,722 23,218 61,673 30.9 37.1 48.5 52.5 51.7 49.9 37.1 22.8 42.9 12,221 13,164 14,930 17,814 18,659 19,797 20,538 21,930 58,129 752 789 909 1,093 1,025 1,120 1,183 1,287 3,544 5.8 5.7 5.7 5.8 5.2 5.36 5.4 5.5 5.7 136 144 183 285 299 291 317 317 747 170 157 177 252 261 282 280 282 755 35 168 126 240 156 143 123 134 569 482 656 675 797 621

E: MOFSL Estimates





S H Kelkar

Bloomberg	SHKL IN
Equity Shares (m)	144.6
M. Cap. (INR b)/(USD b)	22 / 0
52-Week Range (INR)	264 / 137
1,6,12 RelPerf. (%)	-5 / -34 / -58

Financia	Snaps	hot (INR	Billion
----------	-------	-------	-----	---------

Y/E MARCH	FY18	FY19E	FY20E	FY21E
Net Sales	10.4	10.8	12.4	14.4
EBITDA	1.6	1.6	2.0	2.4
Adj. Net Profit	1.0	0.9	1.1	1.4
Adj. EPS (INR)	7.1	6.4	7.6	9.4
Adj. EPS Gr. (%)	-2.2	-10.3	19.5	24.1
BV/Sh (INR)	59.3	63.8	69.2	75.9
RoE (%)	12.3	10.3	11.4	13.0
RoCE (%)	16.9	13.3	15.4	18.0
Div. Payout (%)	28.9	28.9	28.9	28.9
Valuations				
P/E (x)	22.7	25.3	21.2	17.1
P/BV (x)	2.7	2.5	2.3	2.1
EV/EBITDA (x)	15.2	15.8	12.7	10.3
Div. Yield (%)	1.0	0.9	1.1	1.4

CMP: INR155 Buy

- We expect revenue to grow at a sluggish 4% YoY to INR2,969m in 4QFY19 due to sluggish demand.
- EBIDTA margin is likely to expand 600bp YoY to 16% on weak base quarter performance (a one-time expense had dragged base quarter margins) but remain flat on QoQ basis at 16% in 4QFY19. EBIDTA is likely to grow by 72% YoY to INR466m.
- We estimate adjusted PAT to grow 2.6% YoY to INR237m in 4QFY19.

Key issues to watch for

- Pricing pressure in key raw materials, impacting profitability.
- > CFF acquisition cross-selling opportunities.
- Shift of ingredients from Netherlands to manufacturing plants in India.

Consolidated - Quarterly Earning Model

Y/E March			FY18			FY19				FY19E
_	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Net Sales	2,343	2,219	2,831	2,851	2,374	2,845	2,565	2,969	10,430	10,753
YoY Change (%)	-15.3	-9.5	13.5	15.2	1.3	28.2	-9.4	4.1	-1.6	3.1
Total Expenditure	1,929	1,865	2,255	2,580	2,035	2,467	2,165	2,503	8,808	9,173
EBITDA	414	355	576	271	340	378	400	466	1,622	1,581
Margins (%)	17.7	16.0	20.3	9.5	14.3	13.3	15.6	15.7	15.6	14.7
Depreciation	58	57	58	65	68	76	89	85	238	315
Interest	6	11	7	16	15	19	45	45	40	125
Other Income	51	12	7	154	23	50	50	40	216	162
PBT before EO expense	401	298	517	344	280	334	316	376	1,560	1,303
Extra-Ord expense	0	0	101	28	0	0	0	0	-129	0
PBT	401	298	416	316	280	334	316	376	1,432	1,303
Tax	133	110	144	119	100	49	103	126	506	378
Rate (%)	33.1	36.8	34.7	37.6	35.7	14.6	32.5	33.6	35.3	29.0
Minority Interest & P/L of Asso. Cos.	0	0	0	-16	-7	3	-1	13	-16	6
Reported PAT	268	189	272	213	187	288	214	237	942	919
Adj PAT	268	189	338	231	187	288	214	237	1,025	919
YoY Change (%)	-2.5	-22.4	33.0	-15.9	-30.2	52.8	-36.7	2.6	-2.2	-10.3
Margins (%)	11.4	8.5	11.9	8.1	7.9	10.1	8.3	8.0	9.8	8.5

E: MOFSL Estimates





The Ramco Cements

Bloomberg	TRCL IN
Equity Shares (m)	235.6
M. Cap. (INR b)/(USD b)	175 / 3
52-Week Range (INR)	879 / 546
1,6,12 Rel Perf. (%)	-1 / 6 / -17

52-Week Range (INR)
1,6,12 Rel Perf. (%)

Financial Snapshot (INR Billion)									
Y/E March	2018	2019E	2020E	2021E					
Sales	43.9	49.8	57.4	66.5					
EBITDA	10.7	10.0	12.9	16.1					
NP	5.6	5.0	6.7	8.7					
Adj. EPS (INR)	24.0	21.4	28.5	36.8					
EPS Gr. (%)	-11.9	-10.6	33.1	29.0					
BV/Sh. (INR)	171.6	189.5	214.5	247.8					
RoE (%)	14.5	11.9	14.1	15.9					
RoCE (%)	11.7	9.9	11.7	13.6					
Payout (%)	12.7	16.3	12.2	9.5					
Valuations									
P/E (x)	30.9	34.6	26.0	20.2					
P/BV (x)	4.3	3.9	3.5	3.0					
EV/EBITDA (x)	17.2	17.3	14.2	10.8					
EV/Ton (USD)	154	146	130	123					

CMP: INR741

- 4QFY19 volumes are estimated to grow 10% YoY to 3.02m tons, with growth from underlying markets of south. Average realizations are expected to increase by 5% QoQ to 4,603/ton due to strong prices in the south.
- EBITDA margin is likely to expand 4.8pp QoQ (+0.8pp YoY) to 22.3%. EBITDA/ton (ex-windmill) is estimated at INR 1042 (+INR42 YoY, +INR258 QoQ) due to higher realization.
- PAT is estimated to increase 19% YoY to INR1.6b.
- The stock trades at a P/E of 26x (FY20E) and 20x (FY21E), EV/EBITDA of 14.2x (FY20E) and 10.8x (FY21E), and EV/ton of USD130 (FY20E) and USD123 (FY21E). Maintain Buy.

Key issues to watch out for

- Volume growth recovery and outlook.
- Cement pricing outlook and demand sustainability in south (AP and Tamil Nadu).

Quarterly Performance										(INR m)
Y/E March	FY18					FY19				FY19E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Sales Dispatches (m ton)	2.15	2.15	2.27	2.74	2.61	2.47	2.75	3.02	9.31	10.85
YoY Change (%)	4.1	6.3	14.7	20.2	21.6	14.7	20.8	10.2	11.5	16.5
Realization (INR/ton)	4,607	4,783	4,606	4,571	4,537	4,622	4,392	4,603	4,638	4,538
YoY Change (%)	1.0	-0.1	-1.9	2.7	-1.5	-3.4	-4.7	0.7	0.4	-2.2
QoQ Change (%)	3.5	3.8	-3.7	-0.8	-0.8	1.9	-5.0	4.8		
Net Sales	10,165	10,633	10,534	12,519	12,046	11,806	12,074	13,898	43,851	49,825
YoY Change (%)	5.1	5.0	12.4	23.1	18.5	11.0	14.6	11.0	11.6	13.6
EBITDA	2,781	2,908	2,276	2,694	2,350	2,442	2,110	3,098	10,658	10,000
Margins (%)	27.4	27.3	21.6	21.5	19.5	20.7	17.5	22.3	24.3	20.1
Depreciation	720	718	730	754	735	728	756	776	2,922	2,994
Interest	155	173	160	105	114	131	135	141	592	522
Other Income	176	103	82	218	202	88	96	134	579	520
PBT before EO expense	2,082	2,120	1,467	2,053	1,703	1,671	1,315	2,315	7,723	7,005
Extra-Ord expense	0	-77	-124	288	0	0	0	0	87	0
PBT	2,082	2,197	1,592	1,765	1,703	1,671	1,315	2,315	7,636	7,005
Tax	524	511	364	679	453	527	304	677	2,079	1,961
Rate (%)	25.2	23.3	22.9	38.5	26.6	31.5	23.1	29.3	27.2	28.0
Reported PAT	1,558	1,685	1,227	1,086	1,250	1,145	1,011	1,638	5,557	5,043
Adj PAT	1,558	1,609	1,103	1,374	1,250	1,145	1,011	1,638	5,644	5,043
YoY Change (%)	-0.1	-22.3	-26.4	2.2	-19.8	-28.8	-8.4	19.2	-12.8	-10.6
Margins (%)	15.3	15.1	10.5	11.0	10.4	9.7	8.4	11.8	12.9	10.1

E: MOFSL Estimates

22 May 2019 24





Thermax

Bloomberg	TMX IN
Equity Shares (m)	112.6
M. Cap. (INR b)/(USD b)	106 / 2
52-Week Range (INR)	1205 / 878
1,6,12 Rel Perf. (%)	-14 / -8 / -34

Y/E March	2018	2019E	2020E	2021E
Net Sales	44.6	54.9	64.0	75.3
EBITDA	4.0	4.4	5.9	7.1
Adj. PAT	2.3	2.9	4.1	4.8
EPS (INR)	20.5	25.4	36.3	43.0
EPS Gr. (%)	-1.2	24.0	42.8	18.2
BV/Sh. (INR)	241.1	259.7	287.6	321.2
RoE (%)	8.8	10.2	13.3	14.1
RoCE (%)	9.8	10.0	12.7	13.4
Payout (%)	29.2	25.1	20.0	18.6
Valuations				
P/E (X)	51.5	41.6	29.1	24.6
P/BV (X)	4.4	4.1	3.7	3.3
EV/EBITDA (X)	29.5	27.5	19.8	16.1
Div Yield (%)	0.6	0.6	0.7	0.8

CMP: INR941 Buy

- Revenue is likely to grow 10% YoY, supported by execution pickup in the Energy segment (+20% YoY) and Chemicals segment (+31% YoY) given improvement in orders available for execution.
- Operating profit is expected to register 9% YoY growth to INR1.5b, while operating margin is expected to remain stable at 9.4% during the quarter.
- Net profit is expected to register 29% YoY growth to INR979m supported by lower tax rate (40.3% v/s 37.6% in 4QFY18) and lower share of loss in JV (INR13m loss v/s INR172m loss in 4QFY18). Maintain **Buy**.

Key issue to watch

> Demand environment in domestic and overseas markets

Quarterly Performance (INR m)

		FY18				FY1				
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE	FY18	FY19E
Sales	8,718	10,331	11,170	14,430	10,353	14,276	14,366	15,934	44,649	54,929
Change (%)	-11.0	-3.5	18.3	-3.2	18.7	38.2	28.6	10.4	-0.4	23.0
EBITDA	721	952	955	1,382	693	1,100	1,073	1,496	4,009	4,363
Change (%)	-10.3	3.6	9.1	-20.2	-3.9	15.6	12.4	8.3	-7.4	8.8
As of % Sales	8.3	9.2	8.5	9.6	6.7	7.7	7.5	9.4	9.0	7.9
Depreciation	189	189	208	239	210	235	230	220	824	894
Interest	16	51	25	37	33	39	36	42	129	150
Other Income	241	236	238	450	310	356	313	355	1,164	1,334
Extra-ordinary Items	0	0	0	0	0	0	99	0	0	99
PBT	757	947	961	1,555	761	1,183	1,121	1,589	4,220	4,653
Tax	284	370	378	626	274	434	463	598	1,658	1,768
Effective Tax Rate (%)	37.5	39.0	39.3	40.3	36.0	36.7	41.3	37.6	39.3	38.0
Share of P/L from JV/Minority	-67	-10	3	-172	3	-3	-7	-13	(251.9)	(20.0)
Reported PAT	406	568	586	757	490	745	751	979	2,311	2,865
Change (%)	(17.0)	(27.4)	9.3	73.4	20.6	31.1	28.1	29.3	(1.2)	24.0
Adj PAT	406	568	586	757	490	745	652	979	2,311	2,865
Change (%)	(17.0)	(27.4)	9.3	23.1	20.6	31.1	11.2	29.3	(1.2)	24.0








1. HINDALCO: NEXT PHASE OF GROWTH IS GOING TO BE IN DOWNSTREAM; Satish Pai, MD

- In FY19, the biggest story was the big rise in input cost of coal, of the carbon products as well as furnace oil and caustic soda. All these had a big impact in FY19.
- Happy to say that in Q4, by February-March, saw prices easing. For example, Q3 to Q4, company's cost of production was flat but from March onwards, company is guiding that in Q1 the cost of production will be 3% lower.
- What benefits company when LME goes down is twofold; one, company has a diversified business model. 25% of the aluminium it sells as downstream value-added products benefits company in times of lower LME because it gets an additional EBITDA per ton from that. Company has a chemical business where it sells speciality alumina and hydrates. Third, 38% of company's metal was hedged.
- Company is done with the upstream expansion and that was where Aditya, Mahan and Utkal, which involved nearly \$5 billion (Rs 30,000 crore) of investment.
- Company is starting on a new growth phase which has got two legs to it; one is downstream and involves aluminium and copper. Company is today selling about 300 KT of the 1.295 million aluminium as value added. Want to double that to 600. Company is selling today 245 KT of the 400 KT of copper as value added, want to convert that to nearly 380, so nearly 90% is value added.
- The second is, now the alumina market is very attractive. Company did a brownfield expansion of Utkal which is going to be completed and may even expand further.
- (Doubling the downstream capacity of aluminium. When will that come on stream?) From FY18 to FY19, company already increased 5%. This is the downstream expansion which is going to be modular. Over the next three to five years, one will see company steadily increasing its downstream capacities as well as going into higher value-added products. Goal is to get an additional \$150 per ton of EBITDA 600 KT on top of the metal EBITDA that you get.



2. BSE: WE ARE THE FASTEST STOCK EXCHANGE IN THE WORLD; Ashishkumar Chauhan, MD

- As the market was uncertain in 2018-19, there was a decline in transactions in the equity market. The stocks from where company gets larger revenues are the exclusive stocks listed only on BSE. They contribute nearly half of transaction charges. During last fiscal, daily volumes in those stocks declined from nearly Rs 200 crore to Rs 50 crore a day. That led to an overall dip in revenues.
- India International Exchange, the country's first global exchange based out of the Gift International Financial Centre in Gujarat, is doing exceedingly well. Since it has just commenced operations, have not started charging and hence there is an initial loss. Company has an expense of Rs 30-35 crore on balance sheet. The exchange has reached a turnover of \$2.93 billion daily.
- (Mutual fund biz) growing at 100% year-on-year. For the first time in 10 years, have started charging now and earned Rs 30 crore in revenues in 2018-19. If the



- trend continues for 5-6 years, the MF business will surpass transaction income. Company closed March with 37 lakh transactions and in April, it clocked 43 lakh transactions.
- Exchange (BSE) is the fastest stock exchange in the world, with 6 micro seconds in response time. It is 10 times faster than the second fastest which has 60 micro seconds. In a competitive scenario, where you are the challenger, you have to keep evolving.
- Slowly reducing the money in the balance sheet by way of dividends and buybacks. That will improve the return on capital employed (ROCE).
- Have applied for a joint venture with the US-based Ebix, the largest insurance exchange in the world. They had recently taken over several companies such as ItzCash. This JV is for insurance distribution.
- Company has also applied to the Insurance Regulatory and Development Authority (Irda) for a license. Have also tied up with ICICI Bank and Power Trading Corp (PTC) to set up an energy exchange for trading electricity on spot basis. Company will have a 25% stake in the venture.









1. THE GEOGRAPHY OF INDUSTRIAL GROWTH IN A FEDERAL POLITY

The new political alignments that emerge after 23 May will influence, among other things, the pattern of industrial growth across Indian states. Whoever wins, it is almost certain that regional parties will exercise much power. Rapid industrial growth in their states will no doubt be a priority for them, as also for state governments led by national parties. This is the context in which we need to think about the future geography of industrial growth in a federal polity. In a conference on Growth and Regional Development in India organised by the Institute of Human Development in New Delhi last week, K.V. Ramaswami presented an interesting paper entitled, 'Where have all the factories gone: growth and concentration of sub-national manufacturing activity in India'. The paper demonstrates that just six states, Tamil Nadu, Maharashtra, undivided Andhra Pradesh, Gujarat, Uttar Pradesh and Bengal, account for close to two-thirds of all factories in the organised sector (64.3%) and a similar share of workers in the sector (62.2%).



2. RISING H1B REJECTION RATES CAN ALTER INDIAN IT SERVICES MODEL

There are many weapons used in a trade war. The two that are most often used are complaints to the World Trade Organization or unilateral changes in tariffs against a trading partner as we have seen with the US and China. Non-tariff trade barriers are often more potent and can be used with relative stealth. One such non-tariff barrier, often used on people-centric industries, is the restriction of the free movement of labour. India still gets about 70% of the H1B's issued each year. US consulates in India have considerable latitude. They can act under a current administration's orders to tighten up the H1B regime without any drastic change in US immigration laws. Other similar "work permit" rules in countries such as Australia, Singapore and the UK also vary over time. I spoke recently with Viju George of JP Morgan, a veteran information technology (IT) sector analyst, whose insight I respect.

Read More



3. THE GLOBAL CONSEQUENCES OF A SINO-AMERICAN COLD WAR

A few years ago, as part of a Western delegation to China, I met President Xi Jinping in Beijing's Great Hall of the People. When addressing us, Xi argued that China's rise would be peaceful, and that other countries – namely, the United States – need not worry about the "Thucydides Trap," so named for the Greek historian who chronicled how Sparta's fear of a rising Athens made war between the two inevitable. In his 2017 book Destined for War: Can America and China Escape Thucydides's Trap?, Harvard University's Graham Allison examines 16 earlier rivalries between an emerging and an established power, and finds that 12 of them led to war. No doubt, Xi wanted us to focus on the remaining four. Despite the mutual awareness of the Thucydides Trap – and the recognition that history is not deterministic – China and the US seem to be falling into it anyway. Though a hot war between the world's two major powers still seems far-fetched, a cold war is becoming more likely. The US blames China for the current tensions. Since joining the World Trade Organization in 2001, China has reaped the benefits of the global trading and investment system, while failing to meet its obligations and free riding on its rules. According to the US, China has gained an unfair advantage through intellectual-property theft, forced technology transfers, subsidies for domestic firms, and other instruments of state capitalism. At the same time, its government is becoming increasingly authoritarian, transforming China into an Orwellian surveillance state.









		СМР	TP	% Upside		PS (INF	8)	EPS	Gr. YoY	(%)	P/E	(x)	P/B	3 (x)	ROE	(%)
Company	Reco	(INR)		Downside			•									<u> </u>
Automobiles																
Amara Raja	Buy	628	761	21	28.3	33.3	38.0	2.6	17.6	14.2	18.9	16.5	2.9	2.6	16.1	16.4
Ashok Ley.	Buy	88	113	28	7.0	7.3	6.0	16.9	4.7	-18.0	12.1	14.8	2.7	2.5	24.1	17.7
Bajaj Auto	Neutral	2981	3050	2	165.4	174.3	190.1	9.3	5.4	9.0	17.1	15.7	3.6	3.2	21.9	21.5
Bharat Forge	Buy	468	595	27	22.2	24.5	27.0	20.3	10.4	10.3	19.1	17.3	3.6	3.1	19.8	19.1
Bosch	Neutral	17394	18200	5	541.9	578.4	673.9	15.4	6.7	16.5	30.1	25.8	6.4	5.6	19.9	40.8
CEAT	Buy	985	1277	30	63.6	73.1	91.2	-0.5	14.9	24.7	13.5	10.8	1.3	1.2	10.3	11.7
Eicher Mot.	Buy	20918	23500	12	813.9	877	1,007	1.8	7.8	14.8	23.8	20.8	5.3	4.5	24.4	23.6
Endurance Tech.	Buy	1149	1350	18	36.2	42.9	49.4	24.5	18.4	15.4	26.8	23.2	5.4	4.7	21.7	21.5
Escorts	Neutral	595	724	22	53.2	57.9	60.4	34.7	8.8	4.3	10.3	9.9	1.7	1.5	17.7	15.8
Exide Ind	Buy	210	281	34	9.1	10.9	12.2	10.6	20.2	12.2	19.3	17.2	2.7	2.4	14.0	14.2
Hero Moto	Neutral	2657	2912	10	169.5	176.8	184.7	-8.5	4.3	4.5	15.0	14.4	3.7	3.4	26.1	24.8
M&M	Buy	639	793	24	40.6	44.1	44.4	-0.9	8.5	0.8	14.5	14.4	2.0	1.9	13.1	11.7
Mahindra CIE	Buy	229	290	27	14.1	17.1	19.4	44.7	21.3	13.0	13.4	11.8	1.8	1.5	14.0	13.8
Maruti Suzuki	Buy	6858	8047	17	247.7	277.3	334.4	-7.1	12.0	20.6	24.7	20.5	4.2	3.8	16.4	18.1
Motherson Sumi	Buy	121	186	54	5.3	6.9	7.8	-2.6	31.8	12.0	17.4	15.6	3.2	2.8	19.4	19.1
Tata Motors	Neutral	177	199	13	-4.4	14.2	15.4	PL	LP	8.7	12.4	11.5	0.9	0.9	7.7	7.8
TVS Motor	Neutral	490	480	-2	14.1	18.1	22.9	1.1	28.6	26.2	27.0	21.4	5.8	4.8	23.5	24.6
Aggregate								-21.6	31.3	10.1	19.2	17.4	3.0	2.7	15.4	15.4
Banks - Private				_											_	
AU Small Finance	Buy	697	720	3	13.2	18.2	24.8	28.9	38	36.2	38.3	28.1	5.0	4.3	14.8	16.4
Axis Bank	Buy	773	875	13	18.2	40.0	55.7	1,538.1		39.1	19.3	13.9	2.6	2.2	14.3	17.0
DCB Bank	Buy	230	250	8	10.5	14.0	18.6	32.0	33.2	33.1	16.5	12.4	2.1	1.8	14.1	16.2
Equitas Hold.	Buy	133	160	20	6.3	9.3	12.2	583.7	46.2	31.5	14.4	10.9	1.6	1.5	12.0	14.2
Federal Bank	Buy	101	120	18	6.3	8.0	10.0	32.2	26.7	25.3	12.7	10.2	1.4	1.2	11.4	12.9
HDFC Bank	Buy	2404	2650	10	79.3	94.4	115.6	16.9	19.1	22.4	25.5	20.8	3.9	3.3	16.1	17.2
ICICI Bank	Buy	400	470	17	5.2	21.2	28.5	-52.8	305.8	34.5	18.9	14.0	2.2	2.0	12.4	15.0
IndusInd	Buy	1448	2050	42	53.8	99.4	127.4	-10.6	84.8	28.2	14.6	11.4	2.7	2.2	20.6	21.4
Kotak Mah. Bk	Neutral	1487	1450	-3	37.7	44.1	53.6	16.0	16.8	21.5	33.7	27.8	4.3	3.7	13.2	14.3
RBL Bank	Buy	669	800	20	20.3	25.2	34.8	34.3	24.1	37.8	26.5	19.3	2.7	2.5	12.4	13.5
South Indian	Buy	14	18	30	1.4	2.2	3.1	-26.2	64.4	36.7	6.1	4.5	0.5	0.4	7.4	9.6
Yes Bank	Buy	141	280	99	7.5	14.1	19.8	-59.6	88.6	40.9	10.0	7.1	1.0	0.9	11.0	13.5
Aggregate								9.3	62.9	29.5	22.2	17.1	3.1	2.7	13.7	15.5
BOB	Dine	125	160	28	7.8	14.8	23.9	LP	89.0	61.4	8.5	5.2	0.7	0.6	8.4	12.3
BOI	Buy Neutral	88	90	28	-22.0	3.2	11.7		LP	270.9	27.9	7.5	0.7	0.0	2.4	8.7
	Neutral	261	278	7	17.0	42.3	49.3	Loss	148.5	16.6	6.2	5.3	0.7	0.7	8.2	8.9
Canara Indian Bk	Buy	247	280	13	6.7	24.0	39.6	-74.4	258.3	64.9	10.3	6.2	0.5	0.5	6.7	10.2
PNB	Neutral	86	90	4	-14.6	5.8	11.6	Loss	LP	102	15	7.4	0.7	0.7	4.8	9.1
SBI	Buy	338	380	13	2.6	33.5	37.3	LP	1,199	11.6	10.1	9.0	1.2	1.1	13.4	13.2
Union Bk	Neutral	72	80	12	4.5	12.8	24.6	LP	185.7	92.1	5.6	2.9	0.3	0.3	5.5	9.9
Aggregate	ivcuttat	,,,	- 00	12	4.5	12.0	24.0	Loss	LP	32	10	7.6	0.9	0.8	9.0	10.7
NBFCs								2033				7.0	0.5	0.0	3.0	10.7
Aditya Birla Cap	Buy	95	130	37	4.0	4.3	5.8	25.7	9.0	34.4	22.0	16.4	2.0	1.6	9.9	10.9
Bajaj Fin.	Neutral	3433	2900	-16	69.5	86.8	107.4	60.0	25.0	23.8	39.5	32.0	8.3	6.8	23.2	23.4
Cholaman.Inv.&F				10												
n	Review	1417	-		76.8	88.6	101.0	23.2	15.4	14.1	16.0	14.0	3.0	2.5	20.5	19.5
HDFC	Buy	2114	2330	10	43.1	49.2	56.3	29.6	14.2	14.3	42.9	37.6	4.4	3.9	13.8	14.3
HDFC Life Insur.	Buy	402	475	18	6.3	7.3	9.0	14.4	15.8	22.6	54.9	44.8	3.7	3.1	20.2	20.0
ICICI Pru Life	Buy	347	450	30	8.0	7.8	9.3	-29.5	-1.3	18.2	44.2	37.4	2.0	1.7	15.9	15.7
	Under		_													
Indiabulls Hsg	Review	808	-		95.9	101.9	119.0	5.0	6.3	16.8	7.9	6.8	1.8	1.6	24.3	25.3
Indostar Capital	Buy	356	525	48	26.1	38.4	53.5	2.5	47.1	39.3	9.3	6.7	1.0	0.8	11.1	13.6
L&T Fin Holdings	Buy	125	170	36	11.2	13.1	15.4	64.8	17.3	17.7	9.5	8.1	1.6	1.3	17.7	17.8
LIC Hsg Fin	Buy	525	580	10	48.1	54.3	61.3	21.4	12.8	12.8	9.7	8.6	1.4	1.3	15.9	15.8







		СМР	TP	% Upside	۰ ـ ـ	EPS (INF	5/	FDS	Gr. YoY	(%)	D/F	(x)	P/B	(v)	ROE	: (%)
Company	Reco	(INR)	(INR)	Downside		•	•									FY21E
MAS Financial	Buy	542	700	29	28.1	33.0	39.9	52.5	17.4	21.1	16.4	13.6	2.8	2.4	18.4	19.0
M&M Fin.	Buy	402	540	34	25.3	29.5	34.0	44.7	16.3	15.6	13.7	11.8	2.1	1.9	16.3	16.8
Muthoot Fin	Neutral	619	560	-10	49.2	55.3	64.2	10.8	12.4	15.9	11.2	9.6	2.3	2.0	22.2	22.1
PNB Housing	Buy	788	875	11	71.1	73.2	80.4	40.9	2.9	9.8	10.8	9.8	1.6	1.4	15.6	15.0
Repco Home	Buy	425	550	29	38.4	43.3	49.9	16.6	12.8	15.2	9.8	8.5	1.5	1.3	16.5	16.3
Shriram Cit	ty _{Buy}	1476	2100	42	149.9	165.5	188.6	48.7	10.4	14.0	8.9	7.8	1.3	1.1	15.9	15.7
Shriram Trans.	Buy	1086	1325	22	113.1	129.7	149.7	4.3	14.6	15.4	8.4	7.3	1.3	1.1	17.2	17.0
Aggregate								24.4	14.3	17.0	23.9	20.5	3.6	3.2	15.1	15.4
Capital Goods																
ABB	Sell	1426	1190	-17	12.0	18.3	22.6	12.7	52.9	23.4	77.8	63.0	7.0	6.4	9.0	10.1
Bharat Elec.	Buy	97	115	19	7.1	7.4	7.7	24.0	4.1	3.7	13.1	12.6	2.4	2.1	18.3	17.1
BHEL	Sell	63	60	-5	3.2	3.8	4.5	45.5	18.6	17.9	16.7	14.2	0.7	0.7	4.2	4.9
Blue Star	Neutral	751	770	3	19.5	24.4	31.0	34.7	25.6	26.6	30.7	24.3	6.9	5.7	22.4	23.3
CG Cons. Elec.	Buy	222	270	21	6.0	7.7	9.3	16.1	27.6	21.6	30.1	25.3	11.4	9.1	43.4	42.4
Cummins	Buy	743	950	28	27.4	31.2	34.8	16.4	13.8	11.6	23.9	21.4	4.4	4.1	19.2	19.8
Engineers India	Buy	113	125	11	5.9	6.5	7.5	-8.4	10.4	15.3	17.4	15.1	3.0	2.8	17.1	18.0
GE T&D	Neutral	265	300	13	9.9	11.1	11.8	31.9	12.1	6.7	23.9	22.4	4.5	4.0	19.8	18.7
Havells	Buy	758	871	15	13.8	16.7	20.3	23.0	21.2	21.1	45.3	37.4	9.5	8.2	21.1	21.9
K E C Intl	Buy	291	347	19	19.0	24.2	28.9	6.0	27.7	19.2	12.0	10.1	2.5	2.0	20.7	20.1
L&T	Buy	1448	1850	28	61.4	76.9	96.1	18.7	25.3	24.9	18.8	15.1	2.9	2.5	16.3	18.0
Siemens	Buy	1181	1290	9	25.1	32.5	34.0	27.1	29.5	4.6	36.3	34.7	4.6	4.2	13.3	12.7
Solar Ind	Neutral	1112	1230	11	28.9	35.0	43.9	18.6	21.0	25.6	31.8	25.3	6.7	5.6	23.2	24.1
Thermax	Buy	991	1290	30	25.4	36.3	43.0	24.0	42.8	18.2	27.3	23.1	3.4	3.1	13.3	14.1
Va Tech Wab.	Neutral	309	351	14	23.1	39.0	48.0	-4.0	68.8	23.1	7.1	5.7	1.2	1.0	16.4	17.5
Voltas	Neutral	585	595	2	15.7	17.4	20.5	-9.2	10.8	18.0	33.6	28.5	4.3	3.8	13.3	14.1
Aggregate								18.8	22.1	19.8	22.9	19.1	3.1	2.8	13.5	14.6
Cement																
Ambuja Cem.	Neutral	221	211	-4	6.3	6.8	7.8	2.0	8.7	14.6	32.4	28.3	2.0	2.0	6.3	7.1
ACC	Buy	1612	1913	19	57.3	66.3	85.4	22.1	15.8	28.7	24.3	18.9	2.6	2.4	11.3	13.3
Birla Corp.	Buy	588	583	-1	33.2	45.0	63.2	53.6	35.5	40.4	13.1	9.3	1.0	0.9	7.5	9.8
Dalmia Bhar.	Buy	1088	1319	21	15.6	18.8	31.4	13.3	20.4	66.7	57.8	34.6	1.9	1.9	3.4	5.5
Grasim Inds.	Neutral	866	836	-3	66.2	85.0	98.3	39.8	28.5	15.7	10.2	8.8	1.2	1.1	6.1	6.0
India Cem	Neutral	100	103	3	2.8	5.4	7.8	-14.1	91.5	44.7	18.6	12.8	0.6	0.5	3.1	4.4
J K Cements	Buy	944	1155	22	34.1	41.9	52.7	-16.8	22.9	25.8	22.5	17.9	2.5	2.2	11.5	13.0
JK Lakshmi Ce	Buy	366	407	11	6.0	11.8	20.2	-19.1	96.7	71.5	31.1	18.1	2.6	2.3	8.8	13.6
Ramco Cem	Buy	769	853	11	21.4	28.5	36.8	-10.6	33.1	29.0	27.0	20.9	3.6	3.1	14.1	15.9
Orient Cem	Buy	114	119	5	2.3	4.4	8.1	7.5	89.8	84	25.8	14.0	2.1	1.8	8.3	13.7
Prism Johnson	Buy	90	104	15	3.1	3.8	4.1	123.4	21.3	7.7	23.8	22.1	3.5	3.1	15.6	14.8
Sanghi Inds.	Buy	62	78	25	2.1	3.4	3.3	-43.5	61.9	-2.9	18.6	18.8	0.9	0.8	5.0	4.7
Shree Cem	Buy	20455	23400	14	362.2	470.3	628.1	-6.1	29.8	33.6	43.5	32.6	6.5	5.5	15.9	18.2
Ultratech	Buy	4649	5190	12	89.4	113.0	153.6	4.3	26.4	35.9	41.1	30.3	3.7	3.3	10.1	11.5
Aggregate	·							14.5	27.4	26.3	25.1	19.8	2.5	2.2	9.8	11.3
Consumer																
Asian Paints	Sell	1359	1150	-15	23.1	23.7	28.8	9.1	2.6	21.7	57.4	47.2	12.6	11.6	22.9	25.6
Britannia	Buy	2846	3350	18	48.1	59.2	69.8	15.1	23.1	17.8	48.0	40.8	15.1	14.8	32.5	36.7
Colgate	Buy	1159	1555	34	27.9	32.1	37.0	10.8	15.1	15.2	36.1	31.3	19.5	20.8	54.1	64.2
Dabur	Neutral	383	415	8	8.5	9.2	10.4	9.0	8.5	12.8	41.6	36.9	10.7	9.9	27.2	27.9
Emami	Buy	362	540	49	12.5	14.3	16.4	2.7	14.7	14.5	25.3	22.1	7.3	7.3	29.4	32.9
Future Consume	er Buy	40	58	44	-0.1	0.7	1.6	Loss	LP	136.0	58.3	24.7	6.1	4.9	11.0	21.9
Godrej Cons.	Neutral	659	650	-1	15.1	16.1	18.5	7.2	6.4	15.1	41.0	35.7	8.7	8.0	21.9	23.4
GSK Cons.	Neutral	7417	7470	1	216.1			29.8	6.3	11.8	32.3	28.9	6.8	6.2	22.3	22.4
HUL	Buy	1784	1950	9	28.9	33.1	39.0	18.2	14.3	17.7	53.9	45.8	46.9	44.1	90.1	99.2
ITC	Neutral	305	305	0	10.2	10.8	12.1	14.8	6.6	12.1	28.2	25.1	6.0	5.6	22.2	23.2
Jyothy Lab	Neutral	164	175	7	5.4	6.0	7.4	10.5	11.2	23.1	27.4	22.2	4.3	4.1	16.1	18.8
			-													







Company Reco (INN) (INN) Down-stee FF19E FF20E F72E			СМР	TP	% Upside	E	PS (INF	₹)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Nestle Nestle Nestral 16596 10615 0 178.6 1960 27.2 27.5 9.8 15.9 54.1 46.6 27.5 29.4 51.2 51.2 51.5 27.5 29.8 29.4 29.5 29.5 29.8 51.5 29.4 20.5 29.5 29.8 29.8 29.5 29.8	Company	Reco	(INR)	(INR)	-		FY20E	FY21E			• •						
Page Indis	Marico	Buy	360	425	18	7.2	8.9	10.6	14.2	23.4	19.4	40.5	33.9	13.1	11.4	35.0	35.9
Parage Milk Foods Buy	Nestle	Neutral	10596	10615	0	178.6	196.0	227.2	27.5	9.8	15.9	54.1	46.6	27.5	29.4	51.2	61.0
Parage Milk Foods Buy	Page Inds	Neutral	22340	27515	23	378.3	472.0	573.3	21.6	24.7	21.5	47.3	39.0	25.5	21.9	53.8	56.2
PRIGHIFFINIA PRIGHER P		Buy	244	305	25	15.7	16.7	20.4	51.5	6.3	22.1	14.6	11.9	2.2	1.9	15.9	17.0
PRAG Hygiere Neutral 10804 9800 -9 131.9 163.2 107.6 145 260 249 65.0 52.0 31.7 26.7 52.8 55.1 United Byrew Neutral 1428 1430 0.2 21.3 23.9 129.3 1429 12.2 22.6 59.8 488 40.2 01.0 12.6 6.0 18.4 47.7 36.8 34.8 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 48. 40.4 30.0 10.3 7.7 25.6 23.8 49.4 20.4 20.4 20.4 20.4 20.4 20.4 20.4 20			1202	1135	-6	18.6	21.7	25.2	-2.0	17.2	15.8	55.3	47.8	12.7	10.8	24.6	24.4
United Spirits Buy																	55.7
United Spirits Buy 551 690 25 10,0 13,6 18,4 47,7 36,8 34,8 40,4 30,0 10,3 7,7 25,6 25,6 36,8 36,9 36,9 36,8 34,8 40,4 30,0 10,3 7,7 25,6 25,6 36,9																	
Megregate 1.0																	
Heathbrace Hea		Биу	331	030	23	10.0	13.0	10.4									
Alembic Phar Neutral 530 587 11 31.0 28.5 32.3 41.6 8.2 13.5 18.6 16.4 3.2 2.7 18.0 17.5 Alkem Lab Buy 1688 2170 29 70.9 91.7 109.4 02.3 29.4 19.0 12.8 18.1 14.6 3.2 2.7 18.0 17.5 Alkem Lab Buy 105 1225 21 44.4 48.2 59.1 67.2 15.6 16.6 18.4 15.4 12.1 18.3 34.0 13.0 17.6 17.5 Alyarobindo Buy 688 940 41 42.8 59.1 67.2 15.5 61.6 16.0 70.7 12.1 18.3 13.4 3.0 17.6 17.5 Alyarobindo Buy 688 940 41 42.8 59.1 67.2 10.2 13.5 13.6 10.7 13.5 13.0 13.0 12.2 12.5 13.6 13.0 10.0 12.5 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0									10.0	11.4	10.5	41.3	33.3	11.0	10.7	20.1	30.0
Alkem Labb Buy 1688 2170 29 70.9 91.7 109.4 20.3 29.4 19.2 18.4 15.4 3.2 2.7 18.4 19.4 Alphat Paharma Buy 1015 1225 21 44.4 48.2 56.6 -16.1 8.4 15.4 15.4 15.4 21.1 18.3 3.4 3.0 10. 16.5 17.5 17.5 18.6 19.4 20.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18		Moutral	F20	F07	11	21.0	20 5	22.2	41.6	0.2	12 5	10.6	16.4	2.2	2.7	10.0	177
Ajanta Pharma Buy 1015 1225 21 44.4 48.2 55.6 16.1 8.4 15.4 21.1 18.3 3.4 3.0 17.6 17.5 Aurobindo Buy 668 940 41 42.8 59.1 64.2 02 3.8 1.87 11.3 10.4 2.3 1.9 22.2 19.5 Biocon Neutral 519 670 29 12.4 19.9 23.7 96.6 607 19.2 61.2 12.6 12.9 3.9 13.9 13.0 22.1 19.5 Biocon Neutral 519 670 29 12.4 19.9 23.7 96.6 607 19.2 61.2 12.6 12.9 21.0 19.5 Biocon Neutral 519 488 13 17.6 21.2 53 3.1 8.7 13.3 10.4 2.3 1.9 22.2 19.5 Biocon Neutral 559 488 13 17.5 17.5 17.7 18.8 0.4 15.5 5.8 13.8 13.0 2.2 2.0 17.0 16.0 Cipla Neutral 659 1570 -7 56.0 61.3 70.4 69.5 9.4 14.8 27.6 24.1 21.5 24.2 12.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17																	
Aurobindo Buy 668 940 41 428 591 642 02 381 8.7 11.3 10.4 2.3 1.9 22.2 19.5		•															
Billoton Neutral 519 670 29 124 19.9 23.7 99.6 60.7 19.2 26.1 21.9 4.5 3.9 18.3 19.1 Cadilla Buy 245 420 72 17.5 17.5 18.8 -0.4 1.5 5.8 13.8 13.0 2.2 2.0 17.0 16.5 [cjjal Neutral 559 488 131 76. 21.2 253 -13.6 20.8 19.1 26.3 21.1 27. 24 10.1 10.5 Divis Lab Neutral 1695 1570 -7 56.0 61.3 70.4 69.5 94.8 4.8 27.6 24.1 5.4 4.6 21.1 20.5 Divis Lab Neutral 2663 2700 1 105.2 131.6 134.8 62.6 25.1 2.5 10.5 10.6 16.6 15.0 2.3 21.0 14.0 10.5 Gienmark Neutral 575 560 -3 28.2 31.6 134.8 62.6 25.1 2.5 10.5 10.6 16.6 15.0 2.3 2.0 14.1 13.5 Gienmark Neutral 1795 560 -3 28.2 34.7 38.3 0.9 22.8 10.5 12.7 6.5 14.0 20.5 10.3 8.5 1.6 1.4 16.5 17.8 10.5 10.5 10.5 10.5 10.5 10.5 10.5 10.5		•															
Cadilia Buy 245 420 72 17.5 17.7 18.8 -0.4 1.5 5.8 13.8 13.0 2.2 2.0 17.0 16.0 Cjola Neutral 559 488 13 17.6 21.2 25.3 -13.6 20.8 19.1 26.3 22.1 2.7 2.4 10.1 10.5 Dr. Neutral 1695 1570 -7 56.0 16.3 70.4 69.5 9.4 14.8 27.6 24.1 2.7 2.4 10.1 10.5 Dr. Neddy's Neutral 2663 2700 1 105.2 131.6 13.8 62.6 25.1 2.5 20.2 19.7 2.8 2.5 14.6 13.5 Glemmark Neutral 575 560 -3 28.2 34.7 38.3 -0.9 22.8 10.6 16.5 15.0 2.3 2.0 14.1 13.5 Glemmark Neutral 17.4 1350 6 24.6 28.8 32.9 25.2 17.0 14.4 44.2 38.7 9.6 9.0 21.8 23.1 PCA Labs Buy 909 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 16.7 3.2 2.7 17.0 17.0 17.5 Upliant Life Buy 537 800 49 57.5 661 68.8 26.1 55.0 41.8 1.7 8.1 51.2 12.9 17.2 Laurus Labs Buy 370 470 27 10.4 17.2 25.2 34.5 65.6 46.7 13.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17																	
Gipla Neutral 559 488 -13 17.6 21.2 25.3 -13.6 20.8 19.1 26.3 22.1 2.7 2.4 10.1 10.5 10.5 10.5 10.5 10.5 10.5 10.5	Biocon																19.1
Neural 1695 1570 -7 56.0 61.3 70.4 69.5 9.4 14.8 27.6 24.1 5.4 4.6 21.1 20.5 Dr Reddy's Neural 2663 2700 1 105.2 131.6 134.8 62.6 25.1 2.5 20.2 19.7 28. 25.5 14.6 13.5 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 GSK Pharma Neural 1274 1350 6 24.6 28.8 32.9 25.2 17.0 14.4 4.2 38.7 9.6 9.0 21.8 23.1 IPCA Labs Buy 909 1145 26 36.8 35.8 35.9 25.2 17.0 14.4 4.2 38.7 9.6 9.0 21.8 23.1 IPUA Labs Buy 370 470 27 10.4 17.2 25.2 34.5 65.6 46.7 21.6 14.7 23.2 20.1 10.0 14.2 Lupin Buy 748 930 24 23.3 34.7 44.2 27.1 49.0 27.3 21.5 6.6 2.3 2.1 11.0 14.2 Sanofi India Buy 5506 6930 26 165.5 18.7 20.8 16.7 13.3 11.4 29.4 26.4 5.2 2.0 13.8 13.2 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 36.3 30.2 20.3 20.5 20.5 11.2 20.5 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 30.2 20.7 25.7 16.4 20.0 17.2 2.2 2.0 13.8 13.2 Storrent Pharma Neutral 1601 1500 6 42.7 53.0 72.6 71.5 24.3 14.6 20.0 17.5 2.8 2.5 14.1 14.3 Intrastructure Ashoka Buildcon Buy 239 285 19 13.5 13.4 14.0 52.5 25.4 31.6 31.4 31.6 31.4 31.6 31.4 31.6 31.4 31.6 31.5 31.4 31.6 31.5	Cadila																16.0
Dr Reddy's Neutral 2663 2700 1 105.2 131.6 134.8 62.6 25.1 2.5 20.2 19.7 2.8 2.5 14.6 13: Glenmark Neutral 575 560 -3 28.2 34.7 38.3 -0.9 22.8 10.6 16.6 15.0 2.3 2.0 14.1 13.5 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 GSK Pharma Neutral 1274 1350 6 24.6 28.8 32.9 25.2 17.0 14.4 44.2 38.7 38.7 9.6 9.0 21.8 27.7 IPCA Labs Buy 909 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 16.7 3.2 2.7 17.0 17.7 Iubilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Iubilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Iubilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Iubilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Iubilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.0 17.3 Iubilant Life Buy 537 800 49 57.5 86.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.0 17.3 Iubilant Life Buy 537 800 49 57.5 86.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 10.1 10.1 12.8 Iupin Buy 748 930 24 12.3 34.7 44.2 27.1 49.0 27.3 1.5 16.6 2.3 2.1 11.0 12.8 Sanofi India Buy 550 6930 26 16.5 18.7 520.8 91.6 7 13.3 11.4 29.4 26.4 5.5 2.2 2.0 11.7 12.8 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.6 Sun Pharma Neutral 1601 1500 6 24.7 53.0 72.6 7.1 24.1 37.0 30.1 27.0 2.2 2.0 11.7 12.8 Aggregate	Cipla	Neutral															10.9
Glenmark Neutral 575 560 -3 28.2 34.7 38.3 -0.9 22.8 10.6 16.6 15.0 2.3 2.0 14.1 13.5 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 Granules Buy 90.9 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 16.7 3.2 2.7 17.0 17.7 Inbilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Inbilant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Indignal Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Indignal Buy 748 930 24 23.3 34.7 44.2 -27.1 49.0 27.3 21.5 16.9 2.3 2.1 11.0 14.8 Sanofilidia Buy 5506 6930 26 165.5 18.75 20.8 19.1 14.2 14.9 0 27.3 21.5 16.9 2.3 2.1 11.0 14.8 Sanofilidia Buy 5506 6930 26 165.5 18.75 20.8 19.1 14.3 14.1 29.4 26.4 5.2 4.7 17.8 17.8 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Sun Pharma Buy 40.9 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.2 Torrent Pharma Neutral 10.1 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 51. 4.4 17.9 21.3 Torrent Pharma Neutral 10.1 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.4 30.0 17.2 2.2 2.0 11.7 12.3 Sadohav Buy 2.3 29 295 23 14.4 14.4 15.5 25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.5 Sadohav Buy 2.3 295 295 23 14.4 14.4 15.5 25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.5 Sadohav Buy 2.3 295 25 11.0 19.0 33.8 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Constructions Buy 4.0 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Constructions Buy 4.0 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Constructions Buy 4.0 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Constructions Buy 4.0 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Constructions Buy 4.0 10.2 12.0 10.5 10.1 11.1 1.0 11.5 10.5 10.6 10.5 10.6 10.5 10.6 10.5 10.6 10.5 10.5 10.6 10.5 10.5 10.5 10.5 10.5 10.5 10.5 10.5	Divis Lab	Neutral	1695	1570	-7	56.0	61.3	70.4	69.5	9.4	14.8	27.6	24.1	5.4	4.6	21.1	20.5
Granules Buy 108 150 39 9.2 10.5 12.7 76.5 14.0 20.6 10.3 8.5 1.6 1.4 16.6 17.8 6SK Pharma Neutral 1274 1350 6 24.6 28.8 32.9 25.2 17.0 14.4 44.2 38.7 9.6 9.0 21.8 23.1 PICA Labs Buy 909 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 20.1 16.7 3.2 2.7 17.0 17.0 17.3 17.1 Inchigant Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Laurus Labs Buy 370 470 27 10.4 17.2 25.2 34.5 65.6 46.7 21.6 14.7 2.3 2.0 11.0 14.2 Lupin Buy 748 930 24 23.3 34.7 44.2 -27.1 49.0 27.3 21.5 16.9 2.3 2.1 11.0 12.8 Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 52.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.3 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 12.8 Extracted Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 12.8 Extracted Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 12.8 Extracted Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 12.8 Extracted Pharma Buy 411 603 1500 -6 42.7 53.0 72.6 7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate	Dr Reddy's	Neutral	2663	2700	1	105.2	131.6	134.8	62.6	25.1	2.5	20.2	19.7	2.8	2.5	14.6	13.3
GSK Pharma Neutral 1274 1350 6 24.6 28.8 32.9 25.2 17.0 14.4 44.2 38.7 9.6 9.0 21.8 23.2 1PCA Labs Buy 909 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 16.7 3.2 2.7 17.0 17.3 Ubilaint Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 15.5 1.2 19.5 17.2 Laurus Labs Buy 370 470 27 10.4 17.2 25.2 34.5 65.6 46.7 21.6 14.7 2.3 2.0 11.0 14.5 Laurus Labs Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.5 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Sup Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.3 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate Shiffing Medicare Buy 239 295 23 14.4 14.4 15.5 25.4 4.7 17.6 21.7 9.7 8.0 1.3 1.2 1.2 1.5 Aggregate Buy 239 285 19 13.5 13.4 14.4 15.5 25.4 -0.4 8.1 16.6 15.4 2.0 17.5 2.8 2.5 14.1 14.2 14.2 14.2 14.2 14.2 14.2 14.2	Glenmark	Neutral	575	560	-3	28.2	34.7	38.3	-0.9	22.8	10.6	16.6	15.0	2.3	2.0	14.1	13.5
PCA Labs Buy 909 1145 26 36.8 45.3 54.4 94.1 23.1 20.1 20.1 16.7 3.2 2.7 17.0 17.7	Granules	Buy	108	150	39	9.2	10.5	12.7	76.5	14.0	20.6	10.3	8.5	1.6	1.4	16.6	17.8
Mulaint Life Buy 537 800 49 57.5 66.1 68.8 26.1 15.0 4.1 8.1 7.8 1.5 1.2 19.5 17.2 Laurus Labs Buy 370 470 27 10.4 17.2 25.2 34.5 65.6 46.7 21.6 14.7 2.3 2.0 11.0 14.8 Lupin Buy 748 930 24 23.3 34.7 44.2 27.1 49.0 27.3 21.5 16.9 2.3 2.1 11.0 14.8 Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.8 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 39.2 300.7 32.2 15.0 11.3 13.3 1.2 9.0 11.6 Tournent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.9 Aggregate Tournent Pharma Neutral 125 155 24 27.1 23.5 14.8 13.6 13.4 37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR Constructions Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.5 Aggregate Tournent Pharma Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.5 Aggregate Tournent Pharma Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.5 Aggregate Tournent Pharma Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.5 Aggregate Tournent Pharma 12.5 15.5 14.8 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5	GSK Pharma	Neutral	1274	1350	6	24.6	28.8	32.9	25.2	17.0	14.4	44.2	38.7	9.6	9.0	21.8	23.2
Laurus Labs Buy 370 470 27 10.4 17.2 25.2 -34.5 65.6 46.7 21.6 14.7 2.3 2.0 11.0 14.5 Lupin Buy 748 930 24 23.3 34.7 44.2 -27.1 49.0 27.3 21.5 16.9 2.3 2.1 11.0 12.8 Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 11.3 13.3 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.7 Sun Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.3 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate	IPCA Labs	Buy	909	1145	26	36.8	45.3	54.4	94.1	23.1	20.1	20.1	16.7	3.2	2.7	17.0	17.7
Lupin Buy 748 930 24 23.3 34.7 44.2 -27.1 49.0 27.3 21.5 16.9 2.3 2.1 11.0 12.8 Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.3 Strides Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.5 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 44 17.9 21.2 20.0 15.1 4.6 <t< td=""><td>Jubilant Life</td><td>Buy</td><td>537</td><td>800</td><td>49</td><td>57.5</td><td>66.1</td><td>68.8</td><td>26.1</td><td>15.0</td><td>4.1</td><td>8.1</td><td>7.8</td><td>1.5</td><td>1.2</td><td>19.5</td><td>17.2</td></t<>	Jubilant Life	Buy	537	800	49	57.5	66.1	68.8	26.1	15.0	4.1	8.1	7.8	1.5	1.2	19.5	17.2
Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 Shilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.2 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Strides Pharma Buy 419 546 34 16.2 20.4 23.8 20.7 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate Buy 411 610 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate Buy 121 175 45 10.5 12.4 15.1 24.7 17.6 21.7 9.7 8.0 1.3 1.2 14.6 15.5 IRB Infra Neutral 125 155 24 27.1 23.5 14.8 13.6 -13.4 -37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR Constructions Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.6 Aggregate Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.6 Aggregate Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.4 Aggregate Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.4 Aggregate Buy 492 720 52 11.0 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 17.1 18.1 14.2 14.2 14.2 14.2 14.2 14.2 14.2 14	Laurus Labs	Buy	370	470	27	10.4	17.2	25.2	-34.5	65.6	46.7	21.6	14.7	2.3	2.0	11.0	14.3
Sanofi India Buy 5506 6930 26 165.5 187.5 208.9 16.7 13.3 11.4 29.4 26.4 5.2 4.7 17.8 17.8 5hilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.3 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Strides Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.3 Strides Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate	Lupin	Buy	748	930	24	23.3	34.7	44.2	-27.1	49.0	27.3	21.5	16.9	2.3	2.1	11.0	12.8
Schilpa Medicare Buy 375 465 24 13.9 22.3 24.2 8.2 60.8 8.3 16.8 15.5 2.2 2.0 13.8 13.2 Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Sun Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.5 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate	Sanofi India		5506	6930	26	165.5	187.5	208.9	16.7	13.3	11.4	29.4	26.4	5.2	4.7	17.8	17.8
Strides Pharma Buy 411 635 54 6.9 27.5 36.3 -39.2 300.7 32.2 15.0 11.3 1.3 1.2 9.0 11.0 Sun Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.3 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate		•			24									2.2			
Sun Pharma Buy 409 546 34 16.2 20.4 23.8 20.7 25.7 16.4 20.0 17.2 2.2 2.0 11.7 12.5 Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate 13.5 24.3 14.6 20.0 17.5 2.8 2.5 14.1 14.5 Infrastructure 15 15 15 24 27.1 23.5 14.8 13.6 -13.4 37.1 5.3 8.4 0.6 0.5 11.5 15.5 IRB Infra Neutral 125 155 24 27.1 23.5 14.8 13.6 -13.4 37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR Constructions 15 2 3 3 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering 15 2 3 5 14.4 14.4 15.5 15.5 14.4 14.4 15.5 15.5	· ·	•															
Torrent Pharma Neutral 1601 1500 -6 42.7 53.0 72.6 -7.1 24.1 37.0 30.1 22.0 5.1 4.4 17.9 21.5 Aggregate		•															
Aggregate Ashoka Buildcon Buy 121 175 45 10.5 12.4 15.1 24.7 17.6 21.7 9.7 8.0 1.3 1.2 14.6 15.5 18.8 18.1 14.3 18.1 14.3 18.3 18.4 18.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19		•															
Infrastructure Ashoka Buildcon Buy 121 175 45 10.5 12.4 15.1 24.7 17.6 21.7 9.7 8.0 1.3 1.2 14.6 15.5 IRB Infra Neutral 125 155 24 27.1 23.5 14.8 13.6 -13.4 -37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR KNR Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.6 Aggregate Logistics Allcargo Logistics Buy 104 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Aggregate D B Corp Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.6 Aggregate D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.5 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 14.2 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 2.8 2.9 18.1 19.5 Maggregate Netals		Neutrai	1001	1300	-0	42.7	33.0	72.0									
Ashoka Buildcon Buy 121 175 45 10.5 12.4 15.1 24.7 17.6 21.7 9.7 8.0 1.3 1.2 14.6 15.5 IRB Infra Neutral 125 155 24 27.1 23.5 14.8 13.6 -13.4 -37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR Constructions Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Magnegate									15.5	24.3	14.0	20.0	17.5	2.0	2.5	14.1	14.5
RRB Infra Neutral 125 155 24 27.1 23.5 14.8 13.6 -13.4 -37.1 5.3 8.4 0.6 0.5 11.5 6.7 KNR Constructions Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Engineering Buy 248 1.0 14.2 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Encoror Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Engineering Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 17.5 2.4 2.3 12.1 12.5 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Lagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 13. 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 Ent.Network Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Ent. Metals		Deve	424	475	45	40.5	12.4	45.4	24.7	47.6	24.7	0.7	0.0	4.2	4.2	11.6	45.5
KNR Constructions Sadbhav Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Aggregate Logistics Allcargo Logistics Buy 104 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Concor Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Aggregate D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 Bent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.5 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate Metals																	
Constructions Buy 239 295 23 14.4 14.4 15.5 -25.4 -0.4 8.1 16.6 15.4 2.2 1.9 14.0 13.2 Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Aggregate 9.6 11.0 1.1 1.0 11.5 9.2 Logistics Allcargo Logistics Buy 104 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Concor Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Aggregate D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 Lagran Prak. Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Lagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate Metals		Neutrai	125	155	24	27.1	23.5	14.8	13.6	-13.4	-37.1	5.3	8.4	0.6	0.5	11.5	6.7
Sadbhav Engineering Buy 239 285 19 13.5 13.4 14.0 5.2 -1.1 4.6 17.9 17.1 1.8 1.6 10.5 10.0 Aggregate 9.6 11.0 1.1 1.0 11.5 9.2 Logistics Buy 104 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Concor Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Aggregate 15.6 14.3 14.9 20.1 17.5 2.4 2.3 12.1 12.5 Media D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 Ent.Network Buy 47		Buy	239	295	23	14.4	14.4	15.5	-25.4	-0.4	8.1	16.6	15.4	2.2	1.9	14.0	13.2
Suparagrage																	
Aggregate Aggregate Allcargo Logistics Allcargo Logistics Buy Allcargo Logistics Buy Allcargo Logistics Allcargo Logistics Buy Allcargo Logistics Buy Allcargo Logistics Buy Allcargo Logistics Allcargo Logistics Buy Allcargo Logistics Allcargo Logistics Buy Allcargo Allcargo Buy Buy Allcargo Buy Allcargo Buy Allcargo Buy Buy Allcarg		Buy	239	285	19	13.5	13.4	14.0	5.2	-1.1	4.6	17.9	17.1	1.8	1.6	10.5	10.0
Logistics Allcargo Logistics Buy 104 142 36 8.7 10.1 11.4 19.3 16.2 12.9 10.4 9.2 1.1 0.9 10.7 10.8 Concor Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Aggregate 15.6 14.3 14.9 20.1 17.5 2.4 2.3 12.1 12.5 Media D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.5 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 22ee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate Metals												9.6	11.0	1 1	1.0	11.5	9.2
Allcargo Logistics Buy Allcargo Logistics Logistics Buy Allcargo Logistics Logistics Logistics Logistics Logistics Logistics												3.0				11.5	J.2
Concor Buy 484 564 17 19.9 22.7 26.2 14.9 13.9 15.3 21.3 18.5 2.7 2.5 12.9 14.0 Aggregate 15.6		Ruy	104	1/12	36	27	10 1	11 /	10.2	16.2	12 0	10.4	9.2	1 1	0.0	10.7	10 g
Aggregate 15.6 14.3 14.9 20.1 17.5 2.4 2.3 12.1 12.5 Media D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5 Metals		•															
Media D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.5 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 <td></td> <td>buy</td> <td>404</td> <td>304</td> <td>1/</td> <td>13.3</td> <td>22.1</td> <td>20.2</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		buy	404	304	1/	13.3	22.1	20.2									
D B Corp Buy 196 215 10 15.7 21.5 23.4 -11.1 37.0 9.0 9.1 8.4 1.7 1.5 19.0 17.9 Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5 Metals									15.0	14.5	14.9	20.1	17.5	2.4	2.3	12.1	12.9
Ent.Network Buy 472 720 52 11.0 19.0 33.8 62.0 72.9 77.6 24.8 14.0 2.2 1.9 9.3 14.7 Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate		Dent	100	245	10	15.7	24 5	22.4	11 1	27.0	0.0	0.4	0.4	17	4 F	10.0	17.0
Jagran Prak. Buy 112 140 25 9.1 13.8 15.5 -5.7 51.5 12.9 8.1 7.2 1.5 1.3 19.7 19.2 Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5	· · · · · · · · · · · · · · · · · · ·																
Music Broadcast Buy 57 76 34 2.3 3.0 3.9 25.5 30.6 31.2 19.1 14.6 2.3 2.0 12.7 14.5 PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5 Metals																	14.7
PVR Buy 1810 1950 8 37.8 40.7 50.6 41.7 7.5 24.4 44.5 35.8 5.3 4.7 13.6 13.9 Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5 Metals																	19.2
Sun TV Buy 546 740 36 37.5 41.4 46.5 35.2 10.4 12.2 13.2 11.7 3.8 3.5 30.4 31.1 Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 3.3 2.8 19.1 19.6 Aggregate Metals		•															14.5
Zee Ent. Neutral 348 450 29 16.3 18.9 22.7 35.2 15.8 20.5 18.5 15.3 13.3 2.8 19.1 19.6 Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.5 Metals	PVR	Buy															13.9
Aggregate 18.7 20.4 6.1 15.3 14.5 2.8 2.9 18.1 19.9 Metals	Sun TV	Buy	546	740	36	37.5	41.4	46.5	35.2	10.4	12.2	13.2	11.7	3.8	3.5	30.4	31.1
Metals	Zee Ent.	Neutral	348	450	29	16.3	18.9	22.7	35.2	15.8	20.5	18.5	15.3	3.3	2.8	19.1	19.6
	Aggregate								18.7	20.4	6.1	15.3	14.5	2.8	2.9	18.1	19.9
Hindalco Buy 196 253 29 24.7 22.9 24.5 30.9 -7.3 6.8 8.6 8.0 1.0 0.9 12.3 11.8	Metals																
	Hindalco	Buy	196	253	29	24.7	22.9	24.5	30.9	-7.3	6.8	8.6	8.0	1.0	0.9	12.3	11.8







		CMP	TP	% Upside	E	PS (INF	₹)	EPS	Gr. YoY	(%)	P/E	E (x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
Hind. Zinc	Neutral	255	239	-6	18.8	21.6	21.9	-10.8	14.6	1.7	11.8	11.6	2.8	2.4	25.1	22.3
JSPL	Buy	163	268	64	-1.7	-1.1	23.5	LP	-35.3	LP	NM	6.9	0.6	0.5	-0.4	7.7
JSW Steel	Buy	280	336	20	30.6	20.7	29.3	30.7	-32.2	41.3	13.5	9.6	1.9	1.7	15.1	18.7
Nalco	Buy	49	75	52	8.8	5.7	6.9	71.9	-34.9	20.6	8.6	7.2	0.9	1.0	10.8	13.3
NMDC	Buy	93	132	42	15.3	10.7	12.9	16.6	-29.7	20.1	8.7	7.2	1.1	1.0	12.5	14.2
SAIL	Neutral	50	52	3	6.3	6.1	9.7	2,330.1	-3	60.5	8.3	5.2	0.5	0.5	6.2	9.3
Rain Industries	Buy	106	123	16	20.4	11.7	17.3	-14.0	-42.7	48.0	9.1	6.1	0.8	0.7	8.5	11.9
Vedanta	Sell	165	144	-13	18.1	16.6	17.4	-11.0	-8.2	4.5	9.9	9.5	1.0	0.9	9.8	9.8
Tata Steel	Neutral	474	532	12	88.6	78.6	77.9	27.3	-11.2	-1.0	6.0	6.1	0.8	0.7	13.5	12.0
Aggregate								20.4	-11.6	17.5	10.0	8.5	1.1	1.0	10.8	11.6
Oil & Gas																
Aegis Logistics	Buy	205	276	34	6.9	9.9	11.3	16.3	43.0	14.7	20.8	18.2	4.2	3.6	21.9	21.4
BPCL	Buy	375	452	21	43.4	47.7	51.6	-12.9	9.9	8.2	7.9	7.3	1.7	1.5	22.7	21.8
GAIL	Neutral	339	340	0	29.5	28.4	30.0	44.6	-3.8	5.7	12.0	11.3	1.6	1.4	13.7	13.3
Gujarat Gas	Neutral	163	151	-7	6.3	6.7	7.5	47.4	6.5	13.0	24.4	21.6	4.4	3.8	19.3	18.8
Gujarat St. Pet.	Neutral	185	191	3	14.1	12.7	14.3	18.9	-10.2	12.9	14.6	13.0	1.6	1.5	11.8	12.1
HPCL	Neutral	285	309	8	43.9	51.3	51.6	-7.3	16.8	0.6	5.6	5.5	1.2	1.1	24.0	21.2
IOC	Buy	153	198	29	18.8	18.7	19.7	-23.7	-0.8	5.5	8.2	7.8	1.2	1.1	14.7	14.4
IGL	Buy	308	368	20	11.2	13.0	14.6	18.2	16.5	12.0	23.7	21.1	4.5	3.9	20.4	19.7
Mahanagar Gas	Neutral	856	1007	18	55.3	57.5	59.3	14.3	4.0	3.0	14.9	14.4	3.1	2.8	22.2	20.3
MRPL	Neutral	62	70	13	1.9	10.5	10.4	-84.8	442.7	-0.9	5.9	5.9	0.9	0.8	16.2	14.3
Oil India	Buy	182	237	30	33.5	29.8	30.6	41.9	-11.1	2.6	6.1	6.0	0.6	0.6	10.9	10.6
ONGC	Buy	174	196	12	26.7	29.3	28.9	32.1	10.0	-1.4	5.9	6.0	0.9	0.8	16.0	14.4
PLNG	Buy	240	300	25	14.4	18.5	21.7	3.7	28.5	17.6	13.0	11.1	3.3	3.0	26.4	28.6
Reliance Ind.	Neutral	1340	1431	7	67.2	70.7	80.3	10.4	5.2	13.6	18.9	16.7	1.9	1.7	10.3	10.7
Aggregate	Neatrai	1540	1731		07.2	70.7	00.5	5.9	7.3	6.2	11.7	11.0	1.5	1.4	13.2	12.8
Retail								5.5	7.0						10.2	
Avenue																
Supermarts	Sell	1274	1125	-12	14.5	18.8	24.9	11.9	30.1	32.3	67.7	51.2	11.8	9.6	19.0	20.6
Aditya Birl	la Buy	200	240	40	4.6	2 -		4563	426.2	46.2		2= 2	0.4		10.0	24.0
Fashion	Buy	203	240	19	1.6	3.7	5.4	156.7	126.3	46.2	54.4	37.2	9.1	7.3	18.3	21.9
Future Lifestyle	Buy	466	585	26	8.6	10.8	14.5	30.1	25.4	34.6	43.1	32.1	4.4	4.0	10.7	13.0
Future Retail	Buy	437	580	33	13.7	15.4	17.5	12.2	12.4	13.5	28.3	24.9	4.8	4.0	18.6	17.6
Jubilant Food.	Neutral	1302	1325	2	24.1	29.3	33.1	62.0	21.6	13.0	44.4	39.3	12.1	10.6	27.2	26.9
Shoppers Stop	Neutral	463	520	12	7.8	13.2	15.9	-36.3	70.0	19.9	35.0	29.2	3.8	3.3	11.4	12.1
Spencers Retail	Buy	124	175	41	0.1	0.7	0.8	LP	780.0	16.0	175.1	150.9	6.5	6.2	3.8	4.2
Titan Company	Buy	1248	1310	5	15.7	20.3	26.2	24.0	29.4	29.2	61.6	47.7	17.5	14.6	29.0	33.4
Trent	Buy	371	440	18	2.9	5.8	7.7	11.6	99.2	32.3	63.9	48.3	6.7	5.9	11.1	13.0
V-Mart Retail	Neutral	2248	2450	9	39.5	47.3	57.2	-8.0	19.8	21.0	47.5	39.3	8.2	6.8	18.9	18.9
Aggregate								21.5	31.6	27.2	55.4	43.6	10.5	8.8	18.9	20.2
Technology																
Cyient	Buy	545	730	34	43.4	48.7	52.4	13.4	12.3	7.6	11.2	10.4	2.1	1.9	18.9	18.4
HCL Tech.	Neutral	1057	1200	14	73.6	77.7	90.4	17.6	5.7	16.3	13.6	11.7	3.1	2.8	23.9	25.0
Hexaware	Neutral	358	360	1	19.3	21.2	24.1	16.5	9.7	13.7	16.9	14.8	4.0	3.5	25.1	25.3
Infosys	Buy	709	860	21	37.5	38.5	44.2	15.9	2.7	14.6	18.4	16.1	4.8	4.4	25.8	28.8
L & T Infotech	Neutral	1773	1910	8	86.6	94.0	106.2	30.6	8.6	13.0	18.9	16.7	5.0	4.1	29.8	27.1
Mindtree	Neutral	981	1000	2	44.8	52.7	62.8	53.1	17.6	19.0	18.6	15.6	4.2	3.6	24.3	25.0
Mphasis	Neutral	940	1050	12	56.9	60.8	70.4	29.3	6.7	15.8	15.5	13.4	4.3	3.5	31.0	30.9
NIIT Tech	Neutral	1289	1400	9	67.0	77.4	88.5	47.1	15.6	14.3	16.7	14.6	3.3	2.9	21.4	21.3
Persistent Sys	Buy	610	800	31	44.0	53.3	60.2	8.9	21.2	13.0	11.4	10.1	1.9	1.7	16.9	17.6
•	Under															
Tata Elxsi	Review	840	-		46.6	48.6	57.5	20.2	4.4	18.3	17.3	14.6	3.8	2.8	26.1	22.0
		2100	2010		02.5	00.0	100.6	26.4	7.6	12.0	22 F	21.0	0.0	0.4	20.0	41.4
TCS	Neutral	2109	2010	-5	83.5	89.8	100.0	26.4	7.6	12.0	23.5	21.0	8.9	8.4	39.0	41.4
TCS Tech Mah	Buy	773	2010 890	-5 15	48.5	89.8 54.9	62.1	12.8	13.2	13.1	14.3	12.6	3.2	2.8	39.0 23.1	24.2







		СМР	TP	% Upside	E	PS (INF	R)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE	: (%)
Company	Reco	(INR)	(INR)	Downside	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E					FY20E	FY21E
Zensar Tech	Buy	249	285	15	13.8	16.2	19.0	29.2	17.2	17.5	15.3	13.1	2.5	2.2	17.6	18.0
Aggregate	·							13.7	6.3	12.7	20.4	18.1	5.6	5.2	27.7	28.5
Telecom																
Bharti Airtel	Buy	331	410	24	-8.8	-5.0	-1.8	PL	Loss	Loss	NM	NM	1.8	1.8	-3.1	-1.0
Bharti Infratel	Neutral	276	290	5	13.6	13.1	12.6	-0.3	-3.4	-4.1	21.0	21.9	3.7	4.0	17.2	17.5
Vodafone Idea	Buy	12	20	69	-18.5	-5.1	-4.7	Loss	Loss	Loss	NM	NM	0.5	0.6	-22.7	-21.6
Tata Comm	Neutral	543	600	11	-2.2	12.7	22.0	PL	LP	73.7	42.8	24.6	86.0	19.1	-	127.2
Aggregate								Loss	Loss	Loss	-15	-18.4	1.2	1.3	-8.2	-7.1
Utiltites																
Coal India	Buy	237	240	1	27.4	29.0	29.9	43.0	6.0	2.8	8.2	7.9	6.6	6.1	80.4	76.3
CESC	Buy	717	841	17	89.0	84.1	92.5	43.3	-5.6	10.1	8.5	7.8	1.0	0.9	11.9	12.1
JSW Energy	Neutral	66	77	16	4.2	5.0	5.9	40.2	17.4	18.1	13.3	11.3	0.9	0.8	6.8	7.7
NHPC	Neutral	23	25	10	2.3	2.4	2.4	-7.0	6.9	0.3	9.4	9.4	0.7	0.7	8.0	7.8
NTPC	Buy	128	158	23	10.9	13.1	15.0	22.9	19.7	14.5	9.8	8.6	1.1	1.0	11.4	12.2
Power Grid	Buy	184	232	26	18.3	20.8	22.6	10.4	13.9	8.8	8.9	8.1	1.4	1.3	17.1	16.8
Torrent Power	Buy	242	300	24	18.7	20.5	25.7	-4.6	9.6	25.4	11.8	9.4	1.2	1.1	10.6	12.2
Tata Power	Neutral	64	68	6	2.1	5.3	5.6	-60.5	150.1	5.6	12.2	11.6	1.0	0.9	8.2	8.2
Aggregate								24.9	11.3	7.8	9.1	8.4	1.6	1.5	17.8	17.8
Others																
Brigade Enterpr.	Buy	245	324	32	17.5	16.0	15.0	62.0	-8.5	-6.4	15.3	16.3	1.4	1.3	9.6	8.2
BSE	Buy	602	750	25	38.1	37.2	46.1	-12.4	-2.2	23.7	16.2	13.1	1.1	1.1	6.9	8.5
Castrol India	Buy	146	190	30	7.2	7.6	7.7	2.4	6.4	0.7	19.2	19.1	11.2	10.2	61.4	56.2
Coromandel Intl	Buy	405	542	34	25.2	28.1	31.9	6.5	11.5	13.5	14.4	12.7	3.0	2.6	22.5	21.8
Delta Corp	Buy	183	329	79	7.2	9.2	11.0	23.8	27.9	19.6	20.0	16.7	2.3	2.0	12.1	12.8
Indian Hotels	Buy	149	186	25	2.4	3.2	4.4	257.4	34.3	37.8	47.2	34.2	3.8	3.5	8.4	10.7
Interglobe	Neutral	1476	1444	-2	0.1	67.4	103.1	-99.7	-	53	22	14.3	7.6	6.9	35.5	50.6
Info Edge	Neutral	1868	1800	-4	24.9	33.9	41.9	67.2	36.4	23.5	55.0	44.6	8.6	7.4	16.9	18.1
Godrej Agrovet	Buy	480	609	27	12.5	15.6	19.1	10.9	24.6	22.2	30.7	25.2	5.0	4.4	17.2	18.7
Kaveri Seed	Buy	467	582	25	32.9	36.9	38.8	2.7	12.2	5.3	12.7	12.0	2.6	2.3	21.2	20.3
Lemon Tree Hotel	lBuy	74	90	22	0.5	1.0	1.9	149.7	115.2	94.2	75.3	38.8	6.2	5.3	8.6	14.8
MCX	Buy	827	950	15	28.4	29.7	37.9	34.1	4.4	27.6	27.9	21.8	3.0	2.8	11.1	13.3
Navneet Education	Buy	108	135	25	6.7	8.2	9.7	22.5	22.2	18.5	13.2	11.1	2.6	2.2	21.6	21.6
Oberoi Realty	Buy	557	628	13	22.5	33.5	35.0	78.1	49.2	4.3	16.6	15.9	2.2	2.0	14.2	13.1
Phoenix Mills	Buy	616	785	27	25.0	25.6	28.7	57.8	2.5	12.3	24.1	21.5	2.5	2.3	10.8	11.0
Quess Corp	Neutral	689	730	6	15.9	31.7	41.8	-27.3	99.9	31.8	21.7	16.5	2.5	2.1	15.8	17.6
PI Inds.	Buy	1121	1266	13	29.7	38.0	46.9	11.6	27.8	23.4	29.5	23.9	5.7	4.8	21.0	21.8
Piramal Enterp.	Buy	2228	2974	33	73.7	124.6	151.3	-5.2	68.9	21.5	17.9	14.7	1.5	1.4	8.9	10.1
SRF	Buy	2954	2983	1	113.7	139.5	179.4	60.0	22.7	28.6	21.2	16.5	3.6	3.0	18.3	19.9
S H Kelkar	Buy	153	207	36	6.4	7.6	9.4	-10.3	19.5	24.1	20.1	16.2	2.2	2.0	11.4	13.0
Tata Chemicals	Buy	616	700	14	42.9	45.5	52.9	-10.8	6.1	16.1	13.5	11.7	1.2	1.1	9.1	9.9
Team Lease Serv.	Buv	2903	3500	21	59.1	86.1	122.6	37.4	45.6	42.4	33.7	23.7	7.1	5.4	23.4	26.0
	,															
Trident	Buy	64	81	27	8.4	9.3	10.1	71.2	11.7	8.0	6.9	6.3	1.0	0.9	15.0	15.0





MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Automobiles		· ,	<u> </u>
Amara Raja Batt.	-2.1	-9.5	-22.5
Ashok Leyland	0.8	-7.8	-34.3
Bajaj Auto	-0.8	-2.7	9.6
Bharat Forge	-3.5	-6.4	-32.7
Bosch	-1.1	-4.3	-1.3
CEAT	-2.2	-11.0	-27.1
Eicher Motors	-1.8	-0.5	-29.0
Endurance Tech.	-0.7	-1.0	-6.2
Escorts	1.4	-22.7	-32.5
Exide Inds.	-2.4	-5.1	-14.9
Hero Motocorp	-2.0	-3.0	-24.0
M & M	-2.4	-6.5	-22.7
Mahindra CIE	0.2	1.6	-4.1
Maruti Suzuki	-3.3	-7.8	-18.6
Motherson Sumi	-5.2	-23.3	-44.1
Tata Motors	-7.1	-25.1	-40.4
TVS Motor Co.	-0.8	-5.4	-12.9
Banks - Private			
AU Small Fin. Bank	0.4	13.1	-1.2
Axis Bank	-1.2	0.2	46.2
DCB Bank	-0.6	13.8	27.6
Equitas Holdings	-2.0	-2.0	-17.0
Federal Bank	-2.1	4.5	25.2
HDFC Bank	-1.2	5.0	20.7
ICICI Bank	-1.8	-1.1	38.2
IndusInd Bank	-3.0	-17.9	-24.7
Kotak Mah. Bank	-1.0	8.0	16.7
RBL Bank	-1.7	-1.0	34.0
South Ind.Bank	-1.8	-19.8	-43.9
Yes Bank	-1.8	-44.8	-57.8
Banks - PSU			
BOB	2.0	-0.8	-3.4
BOI	-2.1	-8.7	-10.2
Canara	-2.3	-6.0	6.0
Indian Bk	-3.0	-6.9	-19.6
PNB	-2.5	-4.4	10.2
SBI	-2.0	8.6	37.7
Union Bk	-3.6	-21.1	-17.7
NBFCs	-0.3	F 0	24.1
Aditya Birla Cap		-5.0	-34.1
Bajaj Fin.	0.8	13.9	63.1
Cholaman.Inv.&Fn	-0.9	-3.8	-8.1
HDFC Life Incur	-0.2	5.5	16.1
HDFC Life Insur.	1.5	-0.9 1.0	-17.8
Indiabulls Hsg Indostar Capital	-0.3	1.0	-27.1
· · · · · · · · · · · · · · · · · · ·	-2.7	-12.9	-39.2
L&T Fin.Holdings	-1.0	-14.8	-25.2
LIC Hsg Fin M&M Fin.	-1.1	1.5 -3.7	10.3
Muthoot Fin	-1.7		-12.5
	0.2	0.7	55.2
MAS Financial Serv.	0.1	-9.2 -5.0	-6.6 -16.4
ICICI Pru Life	-3.1	-5.0	-16.4
PNB Housing	1.7	-0.5	-37.4
Repco Home	-3.1	-1.3	-26.4
Shriram City Union	-0.6	-17.7	-31.8
Shriram Trans.	-0.8	-10.5	-22.9
Capital Goods	-0.4	-0.4	10 6
ABB	-0.4	-0.4	18.6

Company	1 Day (%)	1M (%)	12M (%)
Bharat Elec.	-2.8	4.7	-17.7
BHEL	-4.2	-16.5	-15.8
Blue Star	3.4	13.5	6.8
CG Cons. Elec.	-1.8	-5.8	-7.4
Cummins	-2.6	0.7	0.8
Engineers India	-2.4	-4.3	-19.3
GE T&D	-1.3	0.6	-27.3
Havells	0.2	0.0	44.7
K E C Intl	-0.7	-0.3	-20.3
L&T	-0.7	6.4	10.2
Siemens	-0.2	-0.2	14.4
Solar Ind	-0.7	4.0	0.5
Thermax	-0.9	1.1	-13.6
Va Tech Wab.	4.2	4.3	-32.0
Voltas	-0.7	-5.0	7.5
	-0.7	-5.0	7.5
Cement Ambuia Com	-1.7	-5.7	6.0
Ambuja Cem. ACC	-3.1		
		-5.0	19.9 -19.5
Birla Corp. Dalmia Bhar.	-0.1	13.2	-19.5
	-0.1	0.1	16.6
Grasim Inds.	-2.7	0.1	-16.6
India Cem	-3.0	-9.2	-23.0
J K Cements	4.1	6.2	-1.4
JK Lakshmi Ce	0.0	-1.6	-3.7
Ramco Cem	-1.8	-1.2	-5.5
Orient Cem	2.4	20.9	-5.3
Prism Johnson	-2.4	-10.0	-11.6
Sanghi Inds.	-1.3	-2.0	-36.7
Shree Cem	0.6	4.1	27.2
Ultratech	-2.5	9.4	20.7
Consumer			
Asian Paints	-1.0	-7.3	4.5
Britannia	1.4	-5.1	3.0
Colgate	-0.8	-4.8	-4.0
Dabur	0.0	-5.4	2.8
Emami	-1.5	-8.2	-29.0
Future Consumer	-1.1	-8.8	-26.6
Godrej Cons.	-2.6	-1.4	-8.4
GSK Cons.	-0.8	2.8	25.0
HUL	0.6	2.7	13.0
ITC	-0.6	0.3	8.2
Jyothy Lab	6.0	-11.0	-25.2
Marico	-0.9	-1.1	16.4
Nestle	-1.7	-3.3	11.8
Page Inds	-0.9	-6.0	-2.6
Parag Milk	-2.5	-0.3	-26.1
Pidilite Ind.	-1.3	-4.1	9.8
P&G Hygiene	0.0	0.8	17.4
United Brew	4.4	1.0	25.1
United Spirits	-0.4	-0.2	-11.6
Healthcare			
Alembic Phar	0.1	-0.8	19.4
Alkem Lab	-1.7	-1.9	-12.8
Ajanta Pharma	-1.0	-0.9	2.8
Aurobindo	0.5	-15.1	18.0
Biocon	-1.1	-15.7	-17.3
Cadila	-2.4	-27.4	-30.5
Cipla	-1.2	-0.6	7.5
Divis Lab	2.1	-1.8	49.2






MOSL Universe stock performance


2.9 -0.1 0.1 -0.1 -2.2	-4.9 -10.1 -5.3 -1.9	40.6 14.8 21.5 7.6
0.1 -0.1	-5.3 -1.9	21.5
-0.1	-1.9	
		7.6
-2.2		
	-6.2	36.2
-5.1	-23.4	-31.1
-1.5	-6.3	-17.5
-1.5	-10.4	1.6
0.2	-4.6	11.4
-1.3	-6.0	-8.7
-2.4	-15.8	20.6
-1.2	-11.6	-7.9
-3.3	-12.5	19.8
-0.2	-8.5	-25.9
-2.5	-8.8	-44.6
-0.1	-1.5	-15.1
-1.7	-0.1	-33.4
-0.7	-10.2	-16.6
-2.6	-7.3	-12.8
-0.3	2.5	-26.2
-0.1	-10.0	-25.9
0.0	-4.8	-31.7
0.5	-0.2	-14.8
		35.4
		-41.9
		-37.3
-1.7	-5.4	-14.2
		-12.0
		-32.1
		-9.6
		-32.8
		-17.7
		-52.3
		-32.3
		-29.7
-2.0	-12.8	-17.9
0.4	1 /	10.0
		-19.8
		-4.9
		4.2
		-4.4
		6.5
		-9.0
		-7.2
		18.5
		1.7
-2.3	-12.2	-38.1
-0.5	1.5	-23.8
-1.0	8.8	-6.1
1.8	0.3	14.0
	-3.1	43.8
1.1	-3.1	13.0
1.1	-3.1	13.0
0.6	-8.6	44.7
0.6	-8.6	44.7
	-1.5 0.2 -1.3 -2.4 -1.2 -3.3 -0.2 -2.5 -0.1 -1.7 -0.7 -2.6 -0.3 -0.1 0.0 0.5 0.9 -3.1 -4.2 -1.7 -2.2 -1.1 -2.1 -4.5 -3.1 -2.5 -1.8 -0.7 -2.0 0.4 -4.5 -1.6 -1.4 -1.1 -2.9 -2.6 -2.0 -2.2 -2.3 -0.5 -1.0	-1.5


	4.5 (0/)	424 (0/)	4224 (2/)
Company	1 Day (%)	1M (%)	12M (%)
Jubilant Food	-0.5	-3.2	3.0
Spencer's Retail	-0.3	-10.8	
Shoppers St.	0.9	2.4	-14.3
Titan Co.	1.4	10.9	36.2
Trent	1.3	3.3	11.4
V-Mart Retail	-2.5	-15.5	-1.2
Technology			
Cyient	-2.0	-7.3	-28.6
HCL Tech.	-1.3	-3.9	18.0
Hexaware	0.2	6.1	-16.1
Infosys	-1.8	-1.0	19.9
L&T Infotech	0.8	7.4	16.3
Mindtree	0.1	1.3	-4.4
Mphasis	-0.5	-3.9	-13.1
NIIT Tech	1.3	-1.7	23.0
Persistent Sys	0.5	-2.9	-23.7
Tata Elxsi	-2.5	-12.1	-27.6
TCS	-1.4	-1.7	18.6
Tech Mah	-0.7	-3.2	12.8
Wipro	-1.1	0.7	44.4
Zensar Tech	0.8	4.3	1.9
Telecom			
Bharti Airtel	-2.7	3.9	0.0
Bharti Infra.	2.4	-10.3	-13.8
Idea Cellular	-5.6	-31.3	-62.8
Tata Comm	-2.3	-5.2	-10.9
Utiltites			
Coal India	-0.4	-5.7	-12.0
CESC	-1.1	-1.7	-8.6
JSW Energy	-2.9	-8.5	-5.4
NHPC Ltd	-1.5	-3.6	-12.5
NTPC	-0.5	-5.1	-6.2
Power Grid	-2.1	-5.3	-13.6
Tata Power	-2.2	-8.7	-18.1
Torrent Power	-2.4	-6.4	10.4
Others			
Brigade Enterpr.	0.2	-0.1	2.1
BSE	1.0	-3.4	-25.3
Castrol India	-0.2	-10.4	-12.2
Coromandel Intl	-1.2	-7.8	-8.8
Delta Corp	2.4	-26.3	-20.9
Godrej Agrovet	1.1	-8.1	-20.1
Indian Hotels	0.1	-2.8	7.0
Interglobe	1.3	-5.1	30.3
Info Edge	1.8	-2.2	57.4
Kaveri Seed	-1.8	-2.1	-3.6
Lemon Tree Hotel	-1.9	-5.1	16.5
MCX	-2.2	6.1	12.0
Navneet Educat.	-1.5	-5.1	-21.4
Oberoi Realty	-1.3	1.4	7.7
Phoenix Mills	2.7	0.5	-13.4
PI Inds.	1.4	9.2	32.8
Piramal Enterp.	-2.6	-16.0	-5.3
Quess Corp	-3.6	-3.7	-37.8
SRF	1.3	20.6	57.3
S H Kelkar	-3.0	-0.2	-37.8
Tata Chemicals	1.2	3.3	-16.1
Team Lease Serv.	-0.3	-2.3	7.5
Trident	0.5	-3.8	17.4
UPL	-1.8	6.9	46.5


THEMATIC/STRATEGY RESEARCH GALLERY























REPORT GALLERY

RECENT INITIATING COVERAGE REPORTS























DIFFERENTIATED PRODUCT GALLERY














Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

ion given by the Research Analyst becomes inconsistent with the investment rating legend, the Research Analyst shall within 28 days of the inconsistency, take appropriate measures to make the recommendation consistent with the in

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Securities Ltd. (MOSL*) is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and BSE Limited (BSE), Multi Commodity Exchange of India (MCX) & National Commodity & Derivatives Exchange Ltd. (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products. Details of associate entities of Motilal Oswal Securities Limited are available on the website at

MOSL, it's associates, Research Analyst or their relative may have any financial interest in the subject company. MOSL and/or its associates and/or Research Analyst may have actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. MOSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or self the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. MOSL and/or its associates may have received any compensation from the subject company in the past 12 months.

In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, MOSL or any of its associates may have:

a) managed or co-managed public offering of securities from subject company of this research report,

- managed of containing of securing of securing of securing securing and containing the securing of the securing of securing of securing sec
- Subject Company may have been a client of MOSL or its associates during twelve months preceding the date of distribution of the research report.

MOSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. To enhance transparency, MOSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions

Terms & Conditions:

This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Companies where there is interest No

Analyst ownership of the stock

A graph of daily closing prices of securities is available at www.bseindia.com. Research Analyst riews on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors' as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors". This document must not be acted on or relied on by persons who are not major institutional investors and will be engaged in only with major institutional investors and will be engaged in only with major institutional investors on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S. MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motifal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S. MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of the U.S. Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of the U.S. Securities International Private Limited. this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 2011294012) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore.

Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

<u>Disclaimer:</u>
The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOŚL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 3080 1000. Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No: 022-30801085.

Registration details of group entities: MOSL: SEBI Registration: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-18-2000; Research Analyst: INH000000412. AMFI: ARN 17397. Investment Adviser: INA000007100.Motifal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670) offers PMS and Mutual Funds products. Motifal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) offers wealth management solutions, *Motilal Oswal Real Estate Investment Advisors Pvt. Ltd. offers Real Estate products. * Motilal Oswal Private Equity Investment Advisors Pvt. Ltd. offers Private Equity products

*MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench, The existing registration no(s) of MOSL would be used until receipt of new MOFSL registration numbers.